 
Protocol Version 6.3 1   Phase I/II Study of Bendamustine in Combination with Ofatumumab , Carboplatin  
and Etoposide for Refractory or Relapsed Aggressive B -cell Lymphomas.  
 
AUTHORS  
 
Principal Investigator  
Joanne Filicko -O’Hara, MD  
 
Co-Investigators  
S. Onder Alpdogan, MD  
Matthew Carabasi, MD  
Jerald Gong, MD  
Margaret Kasner, MD  
Neal Flomenberg, MD  
Ubaldo Martinez, MD  
John L.Wagner, MD  
Dolores Grosso, DNP, CRNP  
Avnish Bhatia, MD  
Andrew Chapman, DO  
Michael Ramirez, MD  
Lewis Rose, MD  
Atrayee Basu -Mallick, MD  
Allison Zibelli, MD  
Christina Brus, MD  
Sameh Gaballa, MD  
Pierluigi Porcu, MD  
Neil Palmisiano, MD  
Lindsay Wilde, MD  
 
Biostatistician  
Inna Chervoneva, PhD  
 
 
Division of Hematologic Malignancies and  
Hematopoietic Stem Cell Transplantation  
Department of Medical Oncology  
Kimmel Cancer Center 
Thomas Jefferson University  
834 Chestnut Street, Suite # 320,  
Philadelphia, Pa 19107  
Phone (215) 503 -5894 
 
Original Date: 7.19.11 (Version 1.0)  
Updated Protocol 
Versions 1.12.12 (Version 1.2)  
7.31.12 (Version 1.3)  
10.4.11 (Version 1.1)  
 
Protocol Version 6.3 2 1.7.13 (Version 2.0) 
4.2.13 (Version 2.1)  
6.5.13 (Version 2.2)  
3.12.14 (Version 3.0)  
12.31.14 (Version 3.1)  
2.4.15 (Version 3.2)  
8.12.15 (Version 4.0)  
9.10.15 (Version 5.0 ) 
11.13.15 (Version 5.1)  
02.11.16 (Version 5.2)  
05.27.16 (Version 6.0 ) 
03.10.17 ( Version 6.1)  
11.16.17 (Version 6.2)  
09.17.18 (Version 6.3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Protocol Version 6.3 3  
 
 
 
 
 
 
INDEX 
STUDY SUMMARY  
1 INTRODUCTION  …………………………………………………… …………………………………………………… …..11 
1.1      BACKGROUND     ………………………………………………………………………………………………………………….. 11   
1.2     INVESTIGATIONAL AGENT-OFATUMUMAB ………………………………………………………………………………….1 3 
1.2.1 Preclinical Data ……………………………………………………………………………………………………… ...13 
1.2.2  Clinical Data …………………………………………………………………………………………………………… .14 
     1.2.3   Adverse Events noted in Follicular Lymphoma Subjects ………………………………… ……………1 4 
     1.2.4    Ofatumumab Combination Therapy ………………………………………………………………………… ..14    
     1.3         INVESTIGATIONAL  AGENT -BENDAMUSTINE ……………………………………………………………….1 5 
      1.4        OFATUMUMAB  AND  BENDAMUSTINE  COMBINATION ………………………………………………….1 6 
      1.5        STUDY  RATIONALE  …………………………………………………………………………………………………….1 7 
      1.6        RATIONALE  FOR  CORRELATIVE  STUDIES …………………………………………………………………….1 7 
  1.6.1    Analysis of the surface expression og CD20 on malignant cells in relap sed aggressive B cel l    
lymphoma…………………………………………………………………………………………………………………………1 7 
  1.6.2    Biologic profile of relapsed and refractory aggressive B cell    lymphoma ……………………1 8 
  1.6.3   Validation of oligo nucleotide based microarray platform for NHL risk stratification …..1 9 
2 STUDY OB JECTIVES …………………………………………………… …………………………………………………… .19 
2.1 PRIMARY OBJECTIVE FOR PHASE I PART OF STUDY ………………………………………………………19  
2.2 SECONDARY OBJECTIVE FOR PHASE I……………………………………………………………………………20  
2.3 PRIMARY OBJECTIVE FOR PHASE II STUDY…………………………………………………………………… 20 
2.4 SECONDARY OBJECTIVES FOR PHASE II STUDY……………………………………………………………..20  
3 STUDY DESIGN …………………………………………………… …………………………………………………… ………. 20 
3.1 GENERAL DESIGN PHASE I …………………………………………………………………………………………….. 20 
3.2           GENERAL DESIGN PHASE II……………………………………………… ……………………………………………2 2 
3.3 PRIMARY STUDY ENDOPINT  PHASE I ……………………………………………………………………………..2 2 
3.4 SECONDARY STUDY ENDPOINTS  PHASE 1 ………………………………………………………………………2 2 
3.5 PRIMARY STUDY  ENDPOINTS  PHASE II …………………………………………………………………………2 2 
3.6 SECONDARY STUDY ENDPOINTS  PHAS E II………………………………………………………………………2 2 
3.7 PRIMARY  SAFETY  ENDPOINTS  ………………………………………………………………………………………23  
4 SUBJECT SELECTION AN D WITHDRAWAL …………………………………………………… ……………………2 3 
4.1 INCLUSION CRITERIA ………………………………………………………………………………………………………..2 3 
4.2 EXCLUSION CRITERIA ………… …………………………………………………………………………………………….2 4 
4.3 SUBJECT RECRUITMENT AND SCREENING ………………………………………………………………………………2 5 
4.4 EARLY WITHDRAWAL OF SUBJECTS ……………………………………………………………………………………...2 6 
4.4.1  When and How to Withdraw Subjects ……………………………………………………………………… …26 
4.4.2  Data Collection and Follow -up for Withdrawn Subjects ……………………………………………… .26 
5 STUDY DRUGS …………………………………………………… …………………………………………………… ……... ......26 
 
Protocol Version 6.3 4    5.1        OFATUMUMAB ………………………………………………………………………………………………………………..2 6 
   5.2        BENDAMUSTINE ………………………………………………… …………………………………………………………... 29 
   5.3        ETOPOSIDE ……………………………………………………………………………………………………………………...3 1 
   5.4        CARBOPLATIN ………………………………………………………………………………………………………………....33  
   5.5        TREATMENT REGIMEN …………………………………………………………………………………………………….3 4 
       5.5.1        Chemotherapy Regimen ………………………………………………………………………………………………. .34 
       5.5.2         Supportive Care ……………………………………………………………………………………………………………3 4 
          5.5.2.1 Pre -medication ………………………………………………………………………………………………………… …..34 
          5.5.2.2 Ofatumum ab infusion ……………………………………………………………………………………………………3 5 
          5.5.2.3 Tumor Lysis prophylaxis ……………………………………………………………………………………………… ..36 
          5.5.2.3 Tumor Lysis Prophylaxis……………………………………………………………………………………………………35  
5.5.2.4 Growth factor support …………………………… ………………………………………………………………………3 5 
          5.5.2.5 Prophylaxis of Pneumocystis  jirovecii ………………………………………………………………………………3 5 
          5.5.2.6 Anti fungal Prophylaxis ………………………………………………………………………………………………… ..35 
          5.5.2.7 Anti viral prophylaxis ……………………………………… …………………………………………………………… ..35 
5.5.2.8  Prophylaxis of CNS Disease.. …………………………………………………………………………………………… ..35 
   5.6 Method for Assigning Subjects to Treatment Grou p……………………… …….. ………… ………………. ……3 5 
     5.7 PREPARATION AND ADMINISTRATION OF STUDY DRUG……………………… …….. ……………… ……………….. 35 
     5.8 SUBJECT COMPLIANCE MONITORING ……………………… …….. ……………… ………………………………………. 36 
     5.9 PRIOR AND CONCOMITANT THERAPY ……………………… …….. ……………… ………………………………………. 36 
     5.10  RECEIVING , STORAGE , DISPENSING AND RETURN ……………………… …….. …………… ……………………….. …36 
5.10 .1 Receipt of Drug Supplies ……………………………..……………… ………………………………………………. 36 
5.10.2  Storage ……………………………..……………… ………………………………………………………………………. 36 
5.10.3  Dispensing of Study Drug ……………………… ……………………………………………... ……..………………3 6 
5.10.4  Return or Destruction of Study Drug ……………………… ……..………… ……………………………… ……3 6 
6 STUDY PROCEDURES …………………………………………………… ………………… ……….3 7 
      6.1       SCHEMA ………………………………………………………………………………………………………………………… …37 
      6.2       STEM CELL MOBILIZATION AND STEM CELL TRANSPLANT ……………………………………………… .37 
      6.3       DOSE D ELAYS AND DOSE REDUCTIONS ……………………………………………………………………………. .38 
            6.3.1 Cycle Delays ………………………… …………………………………………………………………………………………..3 8 
           6.3.2 Dose Reduction of Bendamustine  ………….. …………………………………………………………………………... 38 
           6.3.3 Dose Modific ations of Carboplatin, Etoposide and Ofatumumab  ………………………………………….. 38 
      6.4       DISEASE RESPONSE ………………………………………………………………………………………………………… ..39 
      6.5       CORRELATIVE STUDIES ………………………………………………………………………………………………...… .40 
            6.5.1 Flow Cytometr y for CD20 Expression ………………………………………………………………………………... .40 
            6.5.2 Immunohistochemistry Studies ………………………………………………………………………………………… ..40 
           6.5.3 FISH Studies ……………………………………………………………………………………………………………………. ..40 
           6.5.4 Analysis of EBER ……………………………………………………………………………………………………………… ..40 
            
          6.5.5 Submission of Blood and Bone Marrow Samples ……………………………………………………………………4 1 
          6.5.6 Freezing and Storage ………………………………………………………………………………………………………….4 1 
      6.6 DURATION OF THERAPY  ………………………………………………………………………………………………………...4 1 
      6.7 DURATION OF FOLLOW UP  …………………………………………………………………………………………………….4 1 
6.8 FOLLOW UP /MONITORING  …………………………………………………………………………………………………….4 1 
7 STATISTICAL PLAN …………………………………………………… ………………………………………… ………… ……. 41 
7.1 SAMPLE SIZE DETERMINATION …………………………………………………………………………………………………4 1 
7.2 STATISTICAL METHODS …………………………………………………………………………………………………………..4 2 
7.3 SUBJECT POPULATION (S) FOR ANALYSIS ……………………………………………………………………………………..4 4 
7.4             ANALYSIS  OF MISSIN G DATA ……………………………………………………………………………………………...4 4 
8 SAFETY AND ADVERSE E VENTS………………………………………… ………………………….4 4 
8.1 DEFINITIONS …………………………………………………………………………………………………………………………4 4 
8.2 RECORDING OF ADVERSE EVENTS …………………………………………………………………………………………….… 47 
 
Protocol Version 6.3 5 8.3 STOPPING RULE S…………………………………………………………………………………………………………………… 47 
8.4             LIVER  CHEMISTRY  STOPPING  AND  FOLLOW  UP CRITERIA ………………………………………………….. 47 
8.5 DATA AND SAFETY MONITORING PLAN………………………………………………………………………………………..5 0 
8.5.1  Medical Monitoring and AE/SAE Reporting ……… ………………………………………………………… .……5 0 
8.5.2  Data and Safety Monitoring Committee ……………………………………………………………………… .……5 1 
 
9 DATA HANDLING AND RECORD KEEPING ……………………………………………………………………… .……………5 2 
9.1 CONFIDENTIALITY …………………………………………………………………………………………………….……………..5 2 
9.2 SOURCE DOCUMENTS ………………………………………………………………………………………………….……………5 2 
9.3 CASE REPORT FORMS ………………………………………………………………………………………………………………5 2 
9.4 RECORDS RETENTION ………………………………………………………………………………………………………………5 3 
10 STUDY MONITORING, AU DITING, AND INSPECTI NG………………………………… .…………5 0 
10.1  STUDY MONITORING PLAN…………………………………………………………………………………………………………5 0 
10.2  AUDITING AND INSPECTING …………………………………………………………………………………………………………5 4 
         10.2.1 In dependent External and Internal Audits ………….. ……………………………………………………… ………… 54 
11 ETHICAL CONSIDERATIO NS………………… …………………………………………………… …..5 5 
12 STUDY FINANCES …………………………………………………… ………………………… ………5 5 
12.1  FUNDING SOURCE …………………………………………………………………………………………………………………..5 5 
12.2  CONFLICT OF INTEREST ……………………………………………………………………………………………………………5 5 
13 PUBLICATION PLAN …………………………………………………… ………………………………5 5 
14 REFERENCES …………………………………………………… ………………………………………. 56 
15 APPENDI CES…………………………………………………… …………………………………… 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Version 6.3 6  
 
 
 
 
 
 
 
List of Abbreviations  
ABC 
AE 
ANC Activated B -cell–Type 
Adverse Event 
Absolute Neutrophil Count 
ASCO American Society of clinical Oncology  
ASCT 
AUC Autologous Stem Cell Transplant  
Area Under the Curve  
BOCE Bendamustine, Ofatumumab, Carboplatin and Etoposide  
BUN Blood Urea Nitrogen 
CBC 
CCRRC 
CDC Complete Blood Count 
Clinical Cancer Research Review Commit tee 
Complement Dependent Cytotoxicity  
CD Cluster of Differentiation  
CHOP Cyclophosphamide, Doxorubicin, Vincristine and Prednisone  
CLL Chronic Lymphocytic Leukemia  
CMP Comprehensive Metabolic Panel   
CR Complete R esponse 
CRMO Clinical Research and Ma nagement Office  
DLBCL Diffuse Large B cell Lymphoma  
D5W 5% Dextrose in W ater 
DLT 
DSMC Dose Limiting T oxicity 
Data and Safety Monitoring Committee  
EFS 
EBER Event Free Survival  
Epstein Barr Encoded RNA  
FDA 
FDG 
FISH Food and Drug Administration  
Fludeoxyg lucose 
Fluorescence In Situ H ybridization  
FLIPI Follicular L ymphoma IPI score  
GCB 
GFR Germinal -Center B-cell–like 
Glomerular Filtration Rate  
HAART 
HB 
HC 
HIPAA 
HIV Highly active Antiretroviral Therapy  
Hepatitis B  
Hepatitis C   
Health Insurance Portability  and Accountability Act  
Human Immunodeficiency Virus   
 
Protocol Version 6.3 7 ICE Ifosfamide, Carboplatin, Etoposide  
IHC Immunohistochemistry  
IRB 
IWG Institutional Review Board  
International Working Group  
FC Fludarabine, Cyclophosphamide  
IgG 1k 
IWG 
KCC Immunoglobulin G1 kapp a 
International Working Group  
Kimmel Cancer Center  
KPS Karnofsky Performance Status  
LDH  
M-BACOD 
 
MACOP-B Lactate D ehydrogenase  
Methotrexate with Leucovorin, Bleomycin, Doxorubicin, 
Cyclophosphamide, Vincristine, and D examethasone  
Methotrexate with Leuco vorin, Doxorubicin, Cyclophosphamide, 
Vincristine, Prednisone, and B leomycin 
MCL Mantle Cell Lymphoma  
MTD Maximum Tolerated Dose  
NCCN National Comprehensive Cancer Network  
NCI 
NHL 
NIH 
NS National Cancer Institute  
Non Hodgkin Lymphoma  
National Institute  of Health 
Normal Saline  
OPRR 
OS US Dept of Health & Human Serv./Office for Protection from Research Risk  
Overall survival  
ORR Overall Response Rate  
ProMACE -
CytaBOM   Prednisone, Methotrexate, Doxorubi cin,  Cyclophosphamide, E toposide-
CytaBOM: Cytarabine , Bleomycin, Vincristine, Methotrexate  
PD 
PET Progressive Disease  
Positron Emission Tomography  
PFS Progression Free Survival  
PHI 
PML 
PR Protected Health Information  
Progressive Multifocal L eukoencephalopathy  
Partial Response  
PS Performance Status  
RICE Rituximab, Ifosfamide, Carboplatin, E toposide 
RT 
SAAIPI Radiotherapy  
Second line Age Adjusted I nternational Prognostic Index  
SAE Serious Adverse Event  
SEER Surveillance Epidemiology and End R esults 
SLL Small Lymphocytic L ymphoma  
SWOG South Western Oncology Group  
ULN Upper Limit of N ormal 
 
Protocol Version 6.3 8  
 
 
 
 
 
 
Title Phase I/II Study of Bendamustine in Combination  with 
Ofatumumab , Carboplatin  and Etoposide for Refractory or 
Relapsed Aggressive B -cell Lymphomas.  
Short Title  BOCE in Relapsed/Refractory A ggressive Lymphomas  
Protocol Number  11D.404 
Phase Phase I/II  
Methodology  Phase I – 3x3 design, open label. Phase II - Single arm, open label . 
Study Duration  2 years 
Study Center(s)  Single center 
Objectives  Primary objective for Phase I part of the study : 
Safety and toxicity profile of bendamustine in combination with 
ofatumumab, carboplatin and etoposide for refractory or relapsed 
aggressive B cell lymphomas.  
Secondary objective for Phase 1:  
To determine the Overall Frequency of Response with combination 
bendamustine, ofatumumab, carboplatin and etoposide  for refractory or 
relapsed aggressive B cell lymphomas.  
Primary objective for Phase II  study: 
Determine the Overall Frequency of Response with combination 
bendamustine,  ofatumumab, carboplatin and etoposide  for refractory or 
relapsed aggressive B cell lymphomas.  
Secondary objectives  for Phase II study : 
 To determine CR rate  
 To determine 1 and 2 year progression free survival.  
 To determine 1 and 2 year overall survival.  
 To define safety and toxicity of the combina tion of ofatumumab, 
bendamustine, carboplatin and etoposide  for refractory or relapsed 
aggressive B cell lymphomas.  
 To evaluate the level of CD20 expression in the various biologic 
types of relapsed aggressive B cell lymphomas and to correlate that 
with response to the study regimen.  
Number of Subjects  
(max) 36 
Diagnosis and Main 
Inclusion Criteria  Relapsed/refractory aggressive B cell Non -Hodgkin’s lymphoma  
 
 
Protocol Version 6.3 9 Study Product, Dose, 
Route, Regimen  In the Phase I part of the study a standard 3+3 design will  apply to identify 
dose limiting toxicities (DLT) and to define maximum tolerated dose 
(MTD) of combination bendamustine , ofatumumab, carboplatin, and 
etoposide in refractory and relapsed aggressive B cell lymphomas.  
The Phase II part of the study will be a single-arm, open -label study in 
which all patients will receive combination bendamustine, ofatumumab,  
carboplatin and etoposide at the MTD dose defined in phase I  
Patients will be followed on the study until disease progression, 
unacceptable toxicity, or  withdrawal of consent or for total of 2 years post 
completion of therapy (whichever is earlier).  
 
 Agent Dose Route Schedule 
Ofatumumab  Cycle 1: 300 mg  on 
day 1 (or up to 3 
days prior to day 1) , 
1000 mg on day 3.  
Cycles 2 and 3:  
1000 mg on day 1.  IV  Cycle 1: days 1 (or up 
to 3 days prior to day 1) 
and day 3. 
Cycle 2 and 3: day 1  
Bendamustine  Phase I: as per 
escalating dose 
protocol. 
Phase II: MTD 
achieved in Phase I  IV  Day 1 and 2  
Carboplatin  AUC 5 IV Day 2 
Etoposide  100 mg/m²  IV Day 1, 2 and 3 
Duration of 
administration  3 cycles approximately every 3 weeks  or upon blood cell recovery , 
whichever is later  
Reference therapy  RICE (rituximab, ifosfamide, carboplatin, etoposide).  
Statistical Methodology  A total of 9 to  a maximum of 18 patients will  be enrolled in Phase I part of 
the trial. Twenty four patients will be enrolled in Phase II part of the trial. 
This is based on the Simon Optimal Two -Stage Design with the 
assumption that a n ORR rate of 25% indicates that the treatment is not 
effective an d an ORR rate of 50% indicates that the treatment is effective 
with alpha (type I error) 0.05 and 80% power. The last 6 patients enrolled 
at the MTD level in Phase I will be included in the Phase II part of the 
study. Thus the estimated maximum sample size  will be 36  patients. 
 
 
 
 
 
 
 
 
 

3URWRFRO9HUVLRQ6WXG\6FKHPD)LJXUH











 
Protocol Version 6.3 11 1. INTRODUCTION  
1.1 Background:  
Epidemiology  
According to the Surveillance, Epidemiology and End Results ( SEER) data, around 65,540 
people in the United States  will be diagnosed with and 20,210 will die of non-Hodgkin 
lymphoma s (NHL) in 2010. Aggressive B cell lymphomas consist of  diffuse large B cell 
lymphoma (DLBCL),  the single largest category of all lymphomas,  primary mediastinal large B 
cell lymphoma, T cell rich B cell lymphoma , transformed low grade B cell lymphomas and a 
variant of mantle cell lymphoma (MCL). All the above lymphomas are unified by their B cell 
origin, aggressive behavior and similar standard treatment approach.  Burkitt lymphom a has a 
highly aggressive clinical course and is thus treated with different, more aggressive regimens and 
will not be discussed here.  
 
First Line Treatment  
In the early 1970’s Levitt and DeVita initially described potentially curative combination 
chemothe rapy for large cell lymphomas  (1, 2). Since then, CHOP (cyclophosphamide, 
doxorubicin, vincristine and prednisone) has been widely used in the treatment of aggressive 
NHL. Its superiority over other second and third generation combination chemotherapy (m -
BACOD, ProMACE -CytaBOM, and MACOP -B) was established  by the historic Phase III 
SWOG trial (Fisher RI et al 1993) which showed equal efficacy and superior safety profile of 
CHOP with an overall survival of 54% at three years  (3). 
 
The addition of Rituximab t o chemotherapy  for patients with aggressive B cell lymphoma has 
significantly improved outcome. The use of rituximab in combination with CHOP (RCHOP) vs. 
CHOP in young patients with good prognosis DLBCL has resulted in better PFS and OS . 
Pfreundschuh  et al evaluated RCHOP vs . CHOP in young patients (age 18 -60) with good 
prognosis DLBCL  (4). The 3 year event free survival was 79% in the RCHOP arm vs. 59% in 
the CHOP arm.  Similar improved results were seen in the elderly population. A 10 year follow 
up study of elderly (age 60 -80) patients with DLBCL showed that, 10 year PFS was 36.5% in 
RCHOP arm vs. 20% in the CHOP alone arm  (5). Ten year OS was 43.5% in RCHOP compared 
to 26.7 % in CHOP arm.  
 
Relapsed/Refractory  Aggressive B cell NHL  
Up to 50% of patients with aggressive B cell lymphoma s will relapse after CHOP-like 
chemotherapy with rituximab . There is no standard salvage regimen for patients with relapsed  or 
refractory disease  and at least 75% of patients are expected to succumb to their condition with 
the commonly used rescue regiments.  
 
Prognostic Factors for Relapsed/Refractory  NHL: 
There are various factors that predict outcome in relapsed/refractory lymphomas. These include 
Second Line Age Adjusted International Prognostic Index  (sAAIPI), (see Table 1 and Appendix 
1), initial remission lasting more than 12 months and use of Rituximab in initial therapy. 
Prognostic factors are useful to assess the efficacy of new treatment regimens compared to 
previous approaches. They are also helpful in identifying gro ups which have a poor prognosis 
with existing regimens and may benefit from alternative therapies. sAAIPI  assessed at the 
 
Protocol Version 6.3 12 initiation of second line therapy, predicts the outcome after Autologous Stem Cell Transplant 
(AutoSCT) in patients with relapsed/refr actory lymphomas  (6).  
 
Table 1-sAAIPI assessed at the time of second line therapy  
Risk factors:  Score 
LDH >ULN  1 
Stage III or IV  1 
KPS <80%  1 
 
Low risk (L) with 0  factors, low  intermediate  (LI) risk with 1 factor, high -intermediate risk (HI) 
with 2 factors, and high risk (H) with all 3 factors present . 
 
Treatment of Relapsed/Refractory NHL 
For patients with relapsed/refractory disease, there is no standard salvage regimen.  For patients 
that are eligible for transplant the National Comprehensive Cancer Network ( NCCN) 
recommends a rescue regimen followed by high dose therapy and AutoSCT or high dose therapy 
followed by AlloSCT in selected patients.  
 
Salvage Regimens:  
There are a number of regimens that have been described for relapsed/refractory aggressi ve 
lymphomas in the era of monoclonal antibodies. No regimen has shown clear superiority to the 
other and response rates have ranged between 35 -78% depending on prior rituximab use in 
frontline setting;  uniformly there were  inferior outcomes among patients  who had relapsed after 
a rituximab containing frontline therapy. See table 2 . These inferior clinical outcomes apply to 
our current relapsed patient population  who overwhelmingly ha d previously been treated with  
rituximab containing frontline regiments .  
 
Table 2 
Regimen  Previous 
rituximab 
use sAAIPI>2 CR/Cru ORR OS Author 
R-ICE 0% 47.2% 53% 78% N/A Kewalramani  , 
2004 (7) 
 62% 37.1% 36%* 63.5%*,  47% *(at 3 
years) Gisselbrecht, 
2010 (8) 
DHAP 0% N/A 31% 55% 25% at 2 years  Velasquez , 
1988 (9) 
R-DHAP 62% 38.1% 40%* 62.8%* 51%* (at 3 
years) Gisselbrecht, 
2010 (8) 
R-
ESHAP 56% 35% 45% 73% 55.8% at 29 
months Martin, 2008 
(10) 
R-
EPOCH 16% 58% 28% 68% 35%projected 
OS at 3 yrs  Jermann M, 
2004 (11) 
GEMOX-
R N/A 69% 34% 43% 41% at 1 yr  Lopez A, 2008 
(12) 
*CR, ORR and OS Significantly lower in patients who had prior rituximab  
 
Protocol Version 6.3 13  
RICE (Rituximab, Ifosfamide, carboplatin and Etoposide)  is the most frequently used salvage 
regiment in the United States and DHAP is widely used in Europe. RICE has been developed 
and investigated at the Memorial Sloan -Kettering Cancer center.  Kewalramani et al investigated 
the RICE regimen in 36 patients with aggressive lymphomas that had relapsed after or were 
refractory to single standard anthracycline based chemotherapy  (7). The ORR was  78% and CR 
was 53%.  Among 25 patients who underwent transplantation after RICE 2 year progression free 
survival was 54%.  
 
DHAP (high dose cytarabine with cisplatin and dexamethasone) was studied by Velasquez et al 
in 90 patients with relapsed/ refractory  lymphomas  (9). The ORR was 55% and the CR was 31%. 
Both these regimens were also investigated in a randomized Phase III trial (CORAL study) 
comparing  RICE vs. RDHAP followed by high dose therapy and autologous transplant in 
patients w ith relapsed/refracto ry DLBCL ( 8). The ORR of 63% and 62% with RICE and 
RDHAP, respectively, and the 3 year event free survival was 26% and 35% , respectively 
(p=0.6). Three -year EFS was affected by prior rituximab treatment versus no prior rituximab 
(21% v 47%, respectively).  
 
R-ESHAP (rituximab with etoposide, cytarabine, cisplatin and methylprednisolone) is another 
salvage regimen in relapsed/refractory aggressive lymphomas. Martine et al retrospectively 
evaluated the efficacy of R -ESHAP in 163 patients as a salvage regimen  (10). In the rituximab 
naïve group the CR and ORR was 56% and 81% respectively. In comparison,  the 94 patients 
who had been treated with rituximab earlier the CR and ORR was 37% and 67%. These data 
strongly indicated that rituximab containing salvage regim ens were less effective in the patients 
who were previously treated with a rituximab containing frontline therapy.  
R-EPOCH (rituximab with doxorubicin, etoposide, vincristine, cyclophosphamide and 
prednisone) was evaluated by Jermann et al in 50 patients w ith relapsed/refractory large B cell 
lymphomas and mantle cell lymphomas  (11). The ORR was 68% and CR was 28%.  
GEMOX-R (rituximab  with gemcitabine and oxaliplatin) when studies in 32 patients with 
relapsed/refractory lymphomas had a ORR of 43% and a Cr of  34% (12). 
 
1.2 Investigational Agent- Ofatumumab:  
Ofatumumab is a fully human IgG1κ monoclonal  anti-CD20 antibody. It recognizes a distinct 
epitope encompassing both the large and the small extracellular loops on the human CD20 
molecule expressed on B cel ls. Binding of ofatumumab causes clustering of CD20 on the cell 
surface and promotes cell death through the induction of complement mediated cytotoxicity 
(CDC) and antibody dependent cell mediated cytotoxicity (ADCC). It has been approved by 
FDA for use in  relapsed/refractory CLL  and has been extensively investigated in indolent and 
aggressive B cell NHLs . 
 
1.2.1. Preclinical Data  
In in-vitro studies, Ofatumumab has shown more complement dependent cyto toxicity (CDC) 
than rituximab ( 13). It has similar bindi ng to CD20 as rituximab, but has a slower off rate which  
contributes to increased CDC ( 13). Ofatumumab targets an epitope on the small extracellular 
loop of CD20 in contrast to rituximab which targets only the lar ge extracellular loop of CD20 
 
Protocol Version 6.3 14 (14). This proximity of target may also contribute to increased CDC . Importantly, Ofatumumab 
is able to lyse cells that are insensitive to rituximab due  to their low CD20 -expression ( 13). 
 
1.2.2. Clinical D ata 
Coiffier et al demonstrated the safety and efficacy of ofat umumab in 33 patients with 
relapsed/refractory B cell CLL (1 5). They dose escalated ofatumumab to initial 500 mg infusion 
followed by three 2000 mg infusions. The response rate was 50%. The majority of adverse 
effects occurred at the time of first infusion  and decreased with subsequent infusions. 51% of 
patient’s experienced infectious complication and majority (88%) were Grade 1 or 2.  
Hagenbeek et al reported use of ofatumumab in 40 patients with relapsed/refractory low grade 
(Grade 1 or 2) follicular lym phoma (1 6). They escalated the dose to 4 weekly infusions of 1000 
mg. As seen by Coiffier et al, the majority of adverse effects occurred on the first infusion day 
and declined with subsequent infusions, which was similar to the infusion re actions observed  
with rituximab . Twenty infectious adverse effects were noted and 2 were Grade 3.The clinical 
response ranged from 20% -63%. Based on these studies, it has been established that ofatumumab 
is safe to give as a single agent in B cell lymphomas.  
 
1.2.3. Adverse Events Noted in Follicular Lymphoma Subjects: 
Gastrointestinal: nausea, vomiting, abdominal pain .CGM2008/00147/04  
Respiratory: pharyngolaryngeal pain, dyspnoea , cough, bronchospasm . 
Skin: rash, pruritus, urticaria, flushing . 
General and Administration S ite Conditions: hypotension, influenza -like illness, fatigue, fever, 
chills, headache, dizziness, hyperhidrosis, cytokine release  syndrome, infusion -related reaction . 
Musculoskeletal: arthralgia, myalgia . 
Immune System: hypersensitivity . 
 
1.2.4. Ofatumumab  Combination Therapy  
Ofatumumab  has been evaluated in combination with chemotherapy for treatment of chronic 
lymphocytic leukemia (CLL) and other lymphoid malignancies. Czuczman et al presented 
(ASCO 2010 Abstract No 8042) clinical data  of combination ofat umumab with CHOP 
(cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in previously 
untreated 59 patients with follicular lymphoma  (17). Patients were randomized to 2 groups: 
Ofatumumab dose 500 mg (Group A) or 1,000 mg (Group B). The  combination was well 
tolerated and had a CR/CR unconfirmed of 76% in patients with FLIPI (Follicular lymphoma IPI 
score) of 3 -5 at a median follow up of 9.7 months.  Ofatumumab infusion -related reactions were 
primarily Grade 1-2; 2 patients had Grade 3 rea ctions during first dose, but were able to receive 
subsequent doses. The most common Grade 3-4 adverse events were leukopenia and neutropenia 
(31 and 28%, Group A; 28 and 17%, Group B). Incidences of Grade 3-4 leukopenia and 
neutropenia were 83 and 90% in Group A and 72 and 90% in Group B, respectively. Grade 3 -4 
infections occurred in 10% of pts in Group A and 3% in Group B, with febrile neutropenia in 7 
and 3% of pts, respectively. No deaths have been reported.  
 
Wierda et al (ASCO 2010, abstract 6520)  reported preliminary  results of a phase II trial 
investigating the efficacy and safety of two dose levels of Ofatumumab -FC (fludarabine, 
cyclophosphamide) in previously untreated patients with CLL  (18). Sixty one  patients were 
randomized to ofatumumab 500 mg (Group A) or 1,000 mg (Group B) Day 1, with FC 
 
Protocol Version 6.3 15 chemotherapy. Due to the short follow up (8 months) at the time of presentation, response rates 
were not reported.  The same group published preliminary  results in 2011 (19).  A total of 61 
patients were treate d in the study. Treatment response was assessed using the 1996 N CI 
Guidelines. The CR rate was 32% in patients who received 500 mg of ofatumumab (n=31) and 
50% in patients who received 1000 mg of ofatumumab (n=30). The overall response rate was 
77% in the 500 mg treatment group and 73% in the 1000 mg treatment group. There were no 
unexpected safety findings reported during treatment and within 30 days after last infusion. The 
most common adverse event reported was neutropenia at 48%.  Other common adverse ev ents 
(greater that 15 percent) were nausea, leukopenia, rash, vomiting, pyrexia, headache and 
thrombocytopenia.  The number of patients, who experienced adverse events, including serious 
adverse events, was similar between the two dose groups. One death was  reported and was 
judged by the investigator as unrelated to ofatumumab.  
 
The safety of ofatumumab combinations has been addressed in multiple studies.  
There are  several ongoing trials that are registered on the clinicaltrials.gov website looking at the 
safety and efficacy of ofatumumab in combination with chemotherapy in patients with 
lymphoma. [STUDY_ID_REMOVED] is a randomized trial ‘Ofatumumab Versus Rituximab Salvage 
Chemoimmunotherapy Followed by ASCT in Relapsed or Refractory DLBCL”. This study  plans 
to enroll 380 patients  with relapsed/refractory DLBCL  and has been enrolling since March 2010 . 
Patients are randomized to ofatumumab plus chemotherapy - DHAP (cisplatin, cytarabine and 
dexamethasone) or DVD (DHAP Cycle 1 and 3, VIM -etoposide, ifosfamide and metho trexate 
Cycle 2) or rituximab plus chemotherapy -DHAP or DVD. The primary endpoint of this trial is 
PFS. Another Phase II trial is “A Single Arm, Safety and Efficacy Study of Ofatumumab in 
Combination With ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive 
Lymphoma Prior to Autologous Stem Cell Transplantation ” [STUDY_ID_REMOVED] . In this Phase II 
trial, patients with relapsed/refractory DLBCL, transformed follicular lymphoma or Grade 3b 
follicular lymphoma will be treated with ofatumumab in combination with ICE chemotherapy or 
DHAP chemo therapy prior to autologous stem cell transplantation. The primary endpoint of this 
study is ORR. This study has been open ed and accruing since May 2009 and is expected to be 
completed by December 2011. The Ofatumumab -ICE arm in this trial is comparable to our 
proposed study, except for a novel alkylating agent bendamustine which in our trial will 
substitute ifosfamide .  
 
1.3 Bendamustine  
On October 31, 2008, the U.S. Food and Drug Administration (FDA) approved bendamustin e 
hydrochloride (TREANDA®, Cephalon, Inc.), an intravenously  administered alkylating agent , 
for the treatment of patients with indolent B-cell NHL that progressed during or within six 
months of treatment with rituximab  or a rituximab -containing regimen.  The recommended dose 
for NHL is 120 mg/m2 on day 1 and 2 of each cycle. Bendamustine is an alkylator/purine 
analogue hybrid cytotoxic drug with a distinct pattern of activity, di fferent from other alkylators 
(20).Bendamustine has demonstrated single agent activity in lymphomas refractory to other 
alkylating agents, such as cyclophosphamide. Friedberg et al showed the safety and efficacy of 
single agent Bendamustine in 76 patients with indolent or transformed NHL  that was refractory 
to rituxima b (21). Patients were treated with bendamustine 120 mg/m2 on day 1 and 2 every 3 
weeks for 6 cycles as long as they had a response or stable disease. Fifteen patients required dose 
reduction to 90 mg/m2 and 4 needed reductio n to 60 mg/m2. The most common adverse effects 
 
Protocol Version 6.3 16 were hematological. Grade 3 or 4 neutropenia occurred in 54%, thrombocytopenia in 25% and 
anemia in 12%. The overall response rate was 77% in this study. In another multicenter study, 
Kahl et al evaluated the response to a single agent Bendamustine in 100 patients with rituximab 
refractory indolent B cell lymphoma ( 22). Treatment  consisted of bendamustine 120 mg/m2 on 
day 1 and 2 every 3 weeks for 6 -8 cycles as long as response or stable disease occurred. Twent y 
four patients had dose reductions, 20 patients to 90 mg/m2 and 4 to 60 mg/m2. They achieved a 
similar overall response rate of 75%. Grade 3 or 4 hematological toxicities included neutropenia 
(61%), thrombocytopenia (25%) and anemia (10%).  
 
In in vitro studies, rituximab has shown chemosensitizing effect when used in combination with  
bendamustine  in lymphoma cell lines ( 23). Based on this, Robinson et al investigated the 
efficacy of combination of Bendamustine and Rituximab in 67 patients with relapsed ind olent 
lymphoma and mantle cell lymphoma ( 24). In this study patients received rituximab 375 mg/m2 
on day 1 and bendamustine 90 mg/m2 days 2 and 3 of a 28 -day cycle for 4 -6 cycles. An 
additional dose of rituximab was administered 1 week before the first cyc le and 4 weeks after the 
last cycle.  The combination was well tolerated and the primary toxicity was hematological;  
Grade 3 or 4 neutropenia (36 %), Grade 3 or thrombocytopenia  (9%) and anemia (2%) . Ten 
episodes of Grade 3 or 4 infections occurred. Overall response rate was 93% in indolent 
lymphomas and 92% in mantle cell lymphomas.  
 
Bendamustine has also been used in combination with mitoxantrone and rituximab. Weide et  al 
from the German Lymphoma study group used this combination in 57  patients with  relapsed and 
refractory indolent lymphomas and  mantle cell lymphomas ( 25). Treatment consisted of 
bendamustine  90 mg/m2 on  days 1 and 2, mitoxantrone  10 mg/m2 on day 1 rituximab 375mg/m2  
on day 8; repeated every 4weeks for four cycles. Grade  3 or 4 adverse even ts included anemia 
(10%), thrombocytopenia (16 %), and neutropenia (46%). ORR was 89 %, 92% in follicular 
lymphoma and 78% in mantle cell lymphoma. Vacirca et al presented preliminary data of 
bendamustine and rituximab combination in aggressive B cell lympho mas at 2010 ASCO 
meeting (26). Bendamustine was given at 120 mg/m2 on day 1 and 2 and rituximab 375mg/m2 
on day 1 of a 28 day cycle for 6 cycles. Efficacy data showed ORR of 53% in 17 evaluable 
patients. The combination was safe, in 76 cycles 1 Grade 4 neu tropenia and 9 additional Grade 3 
events. Thus, bendamustine combinations have shown to be effective and can be given safely in 
patients with relapsed lymphomas.  
 
1.4 Ofatumumab and Bendamustine Combinations  
A total of 10 phase I/II and phase III studies of ofatumumab and bendamustine combination 
regiments have been registered to date on the ‘clinicaltrials.gov’ site and at least 5 of them have 
been actively recruiting patients with NHL and CLL. Among them are the following trials:  
 A Phase II study of Ofatumumab and Bendamustine for Previously Treated CLL and 
small lymphocytic lymphoma  (SLL) has been accruing patients since 2009 . Ofatumumab 
is given at 300 -mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 
6 cycles and Bendamustine is giv en at 70 mg/m2 IV on days 1 and 2 of each cycle for 6 
cycles. The primary outcome of the study is the overall response rate.  Clinical trial 
identifier: [STUDY_ID_REMOVED] . 
 A Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine as first -line 
treatment of  Mantle-cell Lymphoma (MCL) in the elderly has been recruiting patients 
 
Protocol Version 6.3 17 since 2010.The starting dose of the 2 main component drugs is the MTD of each drug as 
single agent. Ofatumumab infused iv on day 1 at 300 mg during the first cycle, followed 
by infusio ns of 1000 mg on day 1 of each s ubsequent cycle Bendamustine  infused iv at 
the dose of 120 mg/m2 (days 2, 3 every 21 days) or 120 mg/m2  (days 2, 3 every 28) or 90 
mg/m2 (days 2, 3 every 28 days) depending on toxicity Dexamethasone administered i.v. 
at 40 mg (days 1, 2, 3, 4) . The primary endpoint of the phase II part of the study is the 
complete remission rate.  Clinical trial identifier: NCT 01221103 . 
 A Phase III study of ofatumumab plus bendamustine versus bendamustine  alone has been 
opened for  patients wi th indolent B -cell NHL who did not respond to rituximab or 
progressed on a rituximab -containing regimen during or within six months of  the last 
rituximab treatment. A total of 338 patients in this open label study will be randomized to 
receive either ofatu mumab in addition to bendamustine or bendamustine alone.   Each 
group will receive up to eight cycles of bendamustine while the combination group will 
be given ofatumumab on day one of each cycle.   Once patients in the combination group 
have completed benda mustine therapy, they will continue to receive ofatumumab 
monthly until 12 doses have been given.   The primary endpoint of the study is 
progression free survival.  Clinical trial identifier: [STUDY_ID_REMOVED] . 
1.5. Study Rationale: 
Bendamustine  in combination wit h ofatumumab  containing therapy may present a novel 
attractive salvage regimen for relapsed aggressive B cell lymphomas. We propose a novel RICE -
like salvage combination regimen in which rituximab is substituted with ofatumumab  and 
ifosfamide with bendamus tine in combination with carboplatin and etoposide for refractory or 
relapsed aggressive B cell lymphoma s. We hope to avoid the substantial well recognized 
ifosfamide mediated bladder toxicity (incidence of Grade 3 and 4 hemorrhagic cystitis in 8 -12%) 
and neurologic toxicity (incidence 10 -30%; namely, somnolence, confusion, psychosis and 
seizure) by substituting ifosfamide for bendamustine . Bendamustine  has a single agent activity in 
relapsed aggressive lymphomas, including those refractory to other alkylat ing agents, and has 
shown a favorable safety profile in combination with other chemotherapeutic agents, as noted 
above. The proposed regimen is convenient and,  unlike RICE, can be administered on the 
outpatient basis which presents an additional benefit to  the patients and to the providers.  
 
We will first determine safety and toxicity of escalating dose bendamustine in combination with 
fixed doses of ofatumumab, carboplatin and etoposide. We recognize that the commonly used 
doses of benda mustine in lymphoi d malignancies range from 70 -120 mg/m2 . The recommended 
dose of bendamustine  in NHL is  120 mg/m2 and a dose of 90 mg/m2 has been commonly used 
in combination  regimens. Thus, we propose to initiate bendamustine in combination at a dose of 
70mg/m2 and escala te to a dose of 120 mg/m2.  
 
We will determine maximum -tolerated dose (MTD) and dose -limiting toxicity (DLT) of the 
combination b y using dose escalation of benda mustine from 70mg/m2 in a standard 3 by 3 
design. We will then assess efficacy of the combinatio n regiment at MTD in relapsed and 
refractory aggressive B -cell lymphomas.  
 
1.6 Rationale for the Correlative Studies:  
1.6.1. Analysis of the Surface Expression of CD20 on Malignant Cells in Relapsed 
 
Protocol Version 6.3 18 Aggressive B -cell Lymphomas     
 CD20 is a mature B cell m arker and is present on the surface of most B cell lymphomas  with 
variable level of expression.  Rituximab which is a human/mouse chimeric monoclonal antibody 
is widely used in the treatment of B cell neoplasms. In-vitro studies have shown a transient 
decrease in CD20 expression after treatment with rituximab  (27). When B cell lymphomas  
relapse, the CD20 expression may be decreased, thus making rituximab less effective in the 
relapsed setting. In in-vitro studies, Ofatumumab has shown more complement depende nt 
cytotoxicity (CDC) than rituximab  (12). Importantly, Ofatumumab is able to lyse cells that are 
insensitive to rituximab due to their low CD20 -expression (see section 1. 2). Based on th ese data 
ofatumumab may be more effective at targeting B cells in the relapsed setting. The level of CD 
20 expression on malignant B cells is variable and we will assess the level of CD20 expression in 
patients with relapsed B cell lymphomas. In addition, we will prospectively  evaluate if the level 
of CD20 expression  correlates with the response to the Ofatumumab based combination 
chemotherapy. To assess the level of CD20 expression we will use IHC based scoring system in 
all studied paraffin tissues. In addition, flow cytometry analysis for CD20 expression distribution 
will be performed in all available fresh tissue samples.  
 
1.6.2. Biologic Profile of Relapsed and R efractory Aggressive B -cell Lymphomas  
DLBCL is a group of a ggressive B cell lymphomas which encompass a variety of biologic 
entities with variable clinical and prognostic features. Based on cDNA microarray analysis 
(Rosenwald 2 002), DLBCL have been subdivided into two large prognostic subgroups that 
include germinal -center B-cell– (GCB) and activated B -cell–type (ABC) DLBCL  (28). When 
treated with standard chemoth erapeutic regiments, t he GCB group has significantly better 
prognosis as compared to the ABC .  Hans et al used immunohistochemist ry techniques to further 
characterize the above two prognostic categories  (29). They identified  GCB type as CD10 
positive, Bcl -6 positive and MUM -1 negative  or as CD10 negative, Bcl-6 positive and MUM -1 
negative and non-GCB type as CD10 negative, Bcl -6 negative and MUM -1 positive  or CD10 
negative, Bcl -6 postive and MUM -1 positive . In concert with the data presented by Rosenwald et  
al, the GCB type had an improved overall survival as compared to non -GCB type. In addition, 
Hans et al. assessed Bcl -2 expression in studied samples and Bcl-2 positive subjects had a 
significantly shorter overall survival as compared to Bcl -2 negative. We  will evaluate the rate of 
ABC and GCB type among the accrued patients with relapsed or primary refractory lymphomas 
and will follow them for responses to the investigational regimen.   
 
Novel prognostic subcategories  have recently been identified among ag gressive B cell 
lymphomas.  Among them EBV positive B cell lymphoma of the elderly is an increasingly 
recognized biologic entity. Based on morphology and immunophenotype these cases 
overwhelmingly fall into DLBCL category, however, they have distinct clinic al presentation and 
tend to relapse or show resistance to R -CHOP-like therapy . It is seen in immunocompetent 
elderly subjects and is associated with a wo rse clinical outcome ( 30). In our study, we will assess 
the rate of EBV positive cases among the studie d patients with relapsed and refractory aggressive 
B cell lymphomas. We will evaluate EBER expression in tumor tissue using in -situ hybridization 
technique and  will evaluate response rate to the investigational rescue therapy in this poor 
prognostic group.  
 
 
Protocol Version 6.3 19 ‘Double hit' lymphomas (DH) is a subset of DLBCL with chromosomal breakpoint in cMYC 
locus in combination with another breakpoint , usually Bcl -2, but also BCL -6 (31). These 
lymphomas were recognized  in the 2008 WHO classification as a provisional entity entitled “B 
cell lymphoma unclassifiable with features intermediate between DLBCL and BL.” They have 
an adverse  prognosis when treated with RCHOP based chemotherapy  (31). Cyclin D1+/MYC+ 
represents a variant of mantle cell lymphoma also with a very poor re sponse to s tandard 
chemotherapy and dismal  outcome.   
 
We hypothesize that a high prevalence of the above newly recognized biologic entities will be 
identified in the studied gr oup of patients. We propose to evaluate the rate of the above biologic 
markers in this unfavorable group of patients who have presented with relapsed or primary 
refractory disease . We will assess all available tissue samples for  CD10, Bcl 6 and MUM1 , 
expression  by immunohistochemistry; EBER expression by in -situ hybridization and Bcl-2, Bcl-
6+, Cyclin D1 and cMYC by FISH analysis . We will prospectively assess patients’ clinical 
characteristics and objective  responses to the investigational chemotherapy in these biologically 
determined subgroups.  
 
1.6.3. Validation of Oligonucleotide -based Microarray Platform for NHL Risk 
Stratification  
The combination of karyotype analysis and fluorescence in situ hybridization (FISH) has 
revealed key chromosomal abnormalities  in various hematologic malignancies , such as acute 
myelogenous and acute lym phocytic leukemias, chronic lymphocytic leukemias, myelod ysplastic 
syndrome and multiple myeloma . In contrast, NHL is associated with only a few unique 
chromosomal abnormalities, such as c -Myc, t(11;14), t(14;18) and little is know n yet if other key 
aberrations may be identified and used to risk -stratify large NHL groups, such as DLBCL. A 
novel genome -wide microarray technology reveals submicroscopic chromosome aberrations, 
which can’t be picked by conventional cytogenetic analysis and FISH studies  (32). We propose 
to identify submicroscopic chromosome aberrations in patients with well -defined diagnos es of 
the selected clinically unfavorable group of B cell NHL. We will perform a comprehensive 
biologic profiling of the biopsy samples of the study group as de scribed above and will use 
OncoChip cytogenetcs platform to determine if th ere are identifiable unique biologic and 
cytogenetic features upon which risk -group stratification may develop. The Cancer Microarrays 
Signature OncoChip technology (Signature Genom ic Laboratories ) has the ability to detect 
clinically relevant copy -number imbalances as well as submicroscopic gains and losses not seen 
by conventional cytogenetics. By using microarray platform the OncoChip™ can simultaneously 
identify balanced transloc ations as well as the translocation breakpoints and their partners. We 
will use this comprehensive system to analyze DNA from cryopreserved or fresh diagnostic 
NHL samples. We will assess these submicroscopic chromosomal aberrations in parallel with the 
conventional karyotype and FISH studies. We will determine the feasibility of incorporating a 
newly developed oligonucleotide -based microarray platform into NHL risk stratification 
analysis.  
 
2 STUDY OBJECTIVES   
2.1 Primary Objective for Phase I Part of the  Study: 
To determine the safety and toxicity profile of bendamustine in combination with ofatumumab, 
carboplatin and etoposide for patients with refractory or relapsed aggressive B cell lymphomas.  
 
Protocol Version 6.3 20  
2.2 Secondary O bjective for Phase 1:  
To determine the overall frequency of  response; overall response will include all  subjects with 
complete response (CR) and partial response (PR).   
 
2.3 Primary O bjective for Phase II  Study: 
To determine the overall frequency of response with combination bendamustine, ofatumum ab, 
carboplatin and etoposide  for refractory or relapsed aggressive B cell lymphomas.  
 
2.4 Secondary O bjectives for Phase II S tudy: 
 To determine CR and PR rate  
 To determine 1 and 2 year progression free survival.  
 To determine 1 and 2 year overall survival . 
 Among transplant eligible patients to determine the proportion  of patients who are able to 
undergo stem cell transplant.  
 To define s afety and toxicity of the combination of ofatumumab, bendamustine, 
carboplatin and etoposide  for refractory or relapsed ag gressive B cell lymphomas.  
 To evaluate the level of CD20 expression in the various biologic types of relapsed 
aggressive B cell lymphomas and to correlate that with response  to the study regimen .  
 
3 STUDY DESIGN  
Figure 1
  
 
3.1 General D esign Phase 1 
The Phase I study is designed to identify dose limiting toxicities (DLT) and to define maximum 
tolerated dose (MTD) of bendamustin e in combination with ofatumumab , carboplati n and 
etoposide in refractory and relapsed aggressive B cell lymphomas . Dose escalation  will allow the 
identification of maximum -tolerated dose (MTD) and dose -limiting toxicity (DLT) for 
bendamustine given i.v. on day 1, 2 schedule in combination with fixed doses of ofatumumab, 
 
Protocol Version 6.3 21 carboplatin and etoposide.  At each dose level DLT will be assess ed during a minimum of one 
cycle period.  
 
Schema for Phase 1  
Number of Patients with 
DLT at a Given Dose Level  Escalation Decision Rule  
0 out of 3  Enter 3 patients at the next dose level.  
>2 Dose escalation will be stopped.  This 
dose level will be decl ared the 
maximally administered dose (highest 
dose administered).  Three (3) 
additional patients will be entered at the 
next lowest dose level if only 3 patients 
were treated previously at that dose.  If 
>2 DLT at (-1) dose level, the study 
will be terminat ed. 
1 out of 3  Enter at least 3 more patients at this 
dose level.  
 If 0 of these 3 additional patients 
experience DLT, proceed to the next 
dose level.  
 If 1 or more of th e 3 additional 
patients suffer DLT, then dose 
escalation is stopped, and this dose is 
declared the maximally administered 
dose.  Three (3) additional patients 
will be entered at the next lowest 
dose level if only 3 patients were 
treated previously at that dose.  
<1 out of 6 at highest dose 
level below the maximally 
administered dose  This will be the recommended phase 2 
dose. At least 6 patients must be 
entered at the recommended phase 2 
dose. 
 
Dose Escalation Schedule : 
 
 
 
 
 
 
 
 Dose level  Dose of Bendamustine  
Level 1 70 mg/m² 
Level 2 90 mg/m² 
Level 3 120 mg/m² 
Level -1 50 mg/m² 
 
Protocol Version 6.3 22 3.2 General Design for Phase II  
After MTD of the combination is established from the Phase 1 part of the study, patients with 
relapsed/refractory aggressive B cell -NHL will be enrolled in the Phase II study to determine the 
efficacy of the combination regimen. The Phase II study will be a single -arm, open -label study in 
which all patients will receive combination bendamustine , ofatumumab, carboplatin  and 
etoposide (at the MTD dose  defined in phase I) for a maximum of 3 cycles.  
Patients will be followed on the study  until disease progression, unacceptable toxicity, or 
withdrawal of consent or for total of 2 years post completion of therapy (whichever is earlier).  
 
3.3 Primary Study End Point for Phase I  
Maximum tolerated dose  which is determined using a dose escalati on protocol for bendamustine 
in combination with fixed doses of ofatumumab, carboplatin and etoposide.  
 
3.4. Secondary Study End Point for Phase I  
Overall response frequency which is determined as cumulative complete response (CR) and 
partial response (PR)  in the studied group  
 
3.5 Primary Study End Point for Phase II  
Overall Response  which is determined as cumulative CR and PR in the studied group.  The 2007 
Revised Cheson Criteria for NHL will be used to assess response  (33); see appendix 5 . 
 
CR will be de termined if meets all of the following requirements :  
 PET positive prior to therapy: mass of any size permitted if PET negative. Variably FDG -
avid or PET negative prior to therapy: regression to normal size on CT (≤ 1.5 cm in their 
greatest transverse diam eter for nodes ≥ 1.5 cm before therapy). Previously involved 
nodes that were 1.1 to 1.5 cm in their greatest transverse diameter before treatment must 
have decreased to <1 cm in their greatest transverse diameter after treatment, or by more 
than 75% in the  sum of the products of the greatest diameters (SPD).  
 The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must 
have regressed in size and must not be palpable on physical examination.  
 If bone marrow is known to be involved before treatment , then repeat biopsy documents 
clearance  
 
PR will be determined if meets the following requirements : 
1. ≥ 50% decrease in SPD of up to 6 largest dominant masses  
a. FDG-avid or PET positive prior to therapy: one or more PET positive at  previously 
involved site  
b. Variably FDG -avid or PET negative: regression on CT  
2. No new sites of disease or increase i n the size of the other nodes, liver, or spleen.  
3. Splenic and hepatic nodules must regress by at least 50% in the SPD.  
 
3.6. Secondary Study End Points for Phase II  
1. CR and PR, assessed per the 2007 Revised Cheson Criteria for NHL (33)  
2. 1 and 2 year progre ssion free and overall survival  
3. Safety and toxicity of the combination of bendamustine, ofatumumab, carboplatin and 
etoposide for refractory or relapsed aggressive B cell lymphoma. Toxicity will be 
 
Protocol Version 6.3 23 assessed according to the NIH CTCAE version 4.0 
(http://ctep.cancer.gov/reporting/ctc.html ). Toxicity refers to toxic events during the full 
course of treatment that are attributed as possibly, probably or definitely due to treatment. 
For details of toxici ty assessment see Section 8.0.  
4. Tolerability of the combination of bendamustine, ofatumumab, carboplatin and etoposide 
for refractory or relapsed aggressive B cell lymphomas.  
o Tolerability of this regime will be compared to historical controls who received 
RICE protocol  
o Subjects who discontinue therapy prior to Cycle 3 in order to undergo stem cell 
collection and transplant are considered to have successfully completed therapy.  
5. Among transplant eligible patients, the frequency of subjects who undergo autologo us or 
allogeneic stem cell transplant.  
 
3.7 Primary Safety End P oints    
Toxicities will be graded according to the National Cancer Institute Common Terminology 
Criteria (CTCAE version 4.0). DLT will be defined as any Grade 4 infection, or Grade >/= 3 
non-hematologic toxicity that persists for 7 days or more  
 
4. Subject Selection and Withdrawal  
4.1 Inclusion Criteria:  
1. Age 18 and above  
2. Patients with histologically confirmed aggressive B cell lymphoid malignancy, such as 
DLBCL, including primary mediastinal l arge B cell lymphoma, T cell rich B cell 
lymphoma, “double hit” DLBCL, mantle cell lymphoma, any transformed low grade B 
cell lymphomas or Grade 3 follicular lymphoma  (Grade 3a or 3b)  who were refractory to 
RCHOP-like or any anthracycline base d chemotherap y or relapsed after at least one prior 
combination chemotherapeutic regimen and who are deemed candidates for  a salvage 
type chemotherapy.  
Relapsed disease:  
 Progressive disease after a CR for at least 28 days. Progression will be defined  
according to the Revised Response C riteria for Malignant Lymphoma ( Cheson 
2007 (33). 
 
             Refractory disease:  
 Subjects must meet one of the following criteria:  
 Persistent or progressive lymphoma with a CR of <28 days duration  or with a PR 
of any duration .  Subject s must have received at least 3 cycles of RCHOP -like or 
any anthracycline base chemotherapy  or at least 2 full cycles of HyperCVAD – 
like chemotherapy .             
 Persistent lymphoma and stable disease after at  least 2 cycles of RCHOP -like or 
any anthracy cline base chemotherapy  or at least 1 full cycle of HyperCVAD – 
like chemotherapy  (part A and B).  
 Progressive disease despite at least 1 cycle of RCHOP-like or any anthracycline 
base chemotherapy  or at least 1 cycle (part A or A and B) of HyperCVAD – like 
chemotherapy  
3. Measurable disease, defined by the revised lymphoma criteria  (Cheson 2007). 
 
Protocol Version 6.3 24 4. Absolute neutrophil count ≥1, 500 and platelet count ≥ 75,000, unless due to underlying  
lymphoma.  
5. Left ventricular ejection fraction estimated by MUGA scan or 2D -echocardiogram  of at 
least 45%  Cardiology consult is recommended prior to enrolment if a history of coronary 
artery disease, CHF with estimated LVEF of <50% or clinically significant arrhythmia.    
6. Estimated glomerular filtration rate (GFR) must be ≥ 50 mL/min  
7. Serum bilirubin ≤ 1.5 × upper limit of normal (ULN)  unless deemed elevated secondary 
to lymphoma involvement of the liver or known Gilbert ’s syndrome.  
8. Aspartate transaminase (AST)/alanine transaminase (ALT)  2.5 × ULN ; unless elevated 
secondary to lympho ma involvement of the liver  
9. Alkaline phosphatase  2.5 × ULN ; unless elevated secondary to lymphoma involvement 
of the liver.  
10. Performance status of ECOG 0 -2.  
11. Both potentially A utoSCT or AlloSCT candidates and those who are not transplant 
candidates are el igible for the study.  
12. Capable of understanding the investigational nature, potential risks and benefits of the 
study, and able to provide valid informed consent and HIPAA consent.  
13. Female patients of childbearing potential must have a negative serum pregnan cy test 
within 3 days prior to enrollment.   
14. Male and female patients of reproductive potential must use an effective contraceptive 
method during the study and for a minimum of 1 year after the after study treatment . 
15. Must be able to comply with study and f ollow up requirements  
 
4.2 Exclusion Criteria : 
1. Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as 
specified in the protocol.   Concomitant use of corticosteroids is permitted as clinically 
indicated.   
2.  Use of investigationa l agents within 4 weeks prior to enrollment.  
3. Any anticancer therapy within 3 weeks before study entry. This exclusion does not apply 
to corticosteroid therapy. The patient must have recovered from all acute toxicities from 
any previous therapy.  
4. Radioimmun otherapy (i.e. Zevalin) within 8 weeks of enrollment.  
5. Prior treatment with anti -CD20 monoclonal antibody or alemtuzumab within 4 weeks 
prior to start of therapy.  
6. Autologous stem cell rescue within 12 weeks before study enrollment or those who 
underwent all ogeneic stem cell transplant  within one year of enrol lment. 
7. Known leptomeningeal or parenchymal brain involvement with lymphoma  unless in 
complete remission after treatment  for at least 12 weeks with negative CSF cytology 
within 2 weeks . Prophylaxis of CNS  disease using intrathecal or intraventricular dosing 
of cytotoxic regimens is permitted and should be performed according to the discretion of 
the treating physician.  
8. History of serious organ dysfunction or disease involving the heart, kidney, liver or ot her 
organ system that may place the patient at undue risk to undergo treatment.  
9. Systemic fungal, bacterial, viral, or other infection if not controlled.  Defined as 
exhibiting ongoing signs/symptoms related to the infection and without improvement, 
despite appropriate antibiotics or other treatment.  (May be enro lled if controlled on 
 
Protocol Version 6.3 25 treatment ). 
10. Significant concurrent disease, illness, or psychiatric disorder that would compromise 
patient safety or compliance, interfere with consent, study participation, fo llow up, or 
interpretation of study results.  
11. Subjects who have current active hepatic or biliary disease (with exception of patients 
with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver 
disease per investigator assessm ent) 
12. History of significant cerebrovascular disease in the past 6 months or ongoing event with 
active symptoms . 
13. Clinically significant cardiac disease including unstable angina, acute myocardial 
infarction within six months prior to randomization, congesti ve heart failure (NYHA III -
IV), and arrhythmia unless controlled by therapy, with the exception of extrasystoles or 
minor conduction abnormalities.  
14. Other malignancy, unless the patient has been disease -free for at least 3 years following 
the completion of curative intent therapy, with the following exceptions:  treated non -
melanoma skin cancer, any in situ carcinoma, or cervical intraepithelial neoplasia, 
regardless of the disease -free duration, are eligible for this study if definitive treatment 
for the con dition has been completed . Organ-confined prostate cancer with no evidence 
of recurrent or progressive disease based on prostate -specific antigen (PSA) values are 
also eligible for this study if hormonal therapy has been initiated, or radical 
prostatectomy  or definitive prostate irradiation has been performed.  
15. Positive test for the Human Immunodeficiency Virus (HIV), unle ss undetectable viral 
load within 3 months of enrol lment (HIV RNA less than 48 copies/mL) on HAART 
therapy. 
16. Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. . Patients 
with prior history of Hepatitis B infection, but immune, with only IgG Hepatitis core 
antibody + (HBcAb +) must be checked for hepatitis B virus titers by PCR and if the viral 
load is undete ctable may be enrolled. These patients must receive anti -viral prophylaxis, 
such as lamivudine 100 mg po daily (or an equivalent) starting at least one week prior to 
cycle 1 and continued through the completion of treatment and for 9 months after the last 
dose of ofatumumab. Hepatitis B virus titers by quantitative PCR and HBsAg should be 
checked every month (+/ - 1 week) while on therapy and every 3 months (+/ - 1 month) 
thereafter for 9 months after the last ofatumumab dose. In the event of an early 
termination of the clinical trial for any reason, a treating physician will be determining 
the frequency and the length of follow up studies of hepatitis B virus titers and HBsAg 
status. It is recommended that the patient remains on prophylactic lamivudine or an 
equivalent, as above, regardless of whether the study was continued or terminated. In 
addition, if appropriate consultation with a hepatologist should be obtained . 
17. Positive serology for hepatitis C (HC) defined as a positive test for HCAb if confirmed 
by HC RIBA immunoblot assay (for positive HCAb reflexively perform a HC RIBA 
immunoblot assay on the same sample)  
18. Pregnant or lactating women.  
 
Inclusion of Women and Minorities  
Both men and women of all races and ethnic groups are eligible for this tr ial.   
 
 
Protocol Version 6.3 26 4.3 Subject Recruitment and Screening  
Subjects will be rec ruited from the practices of the Department of Medical Oncology,  Thomas 
Jefferson University . Patients who meet eligibility criteria will be invited by their physician to 
participate in the study. All therapeutic options will be discussed with the patient and the 
patient’s questions will be answered to the patient’s satisfaction. Patients will be asked to read, 
comment/ask questions about the study and then sign the informed consent form befo re study 
procedures are to take place.  
 
Subjects will be screened based on review of previous diagnostic workup including diagnostic 
tissue biopsy and other laboratory parameters.  Another tissue biopsy will be obtained to confirm 
the relapse, if possible a nd if patient is agreeable.  The diagnosis will be confirmed on the basis of 
review of initial diagnostic pathology by our institutional hemato -pathologist. Screening 
laboratory work to be performed will include blood chemistries , viral serologies (for HIV,  
Hepatitis B and Hepatitis C) , pregnancy testing (if applicable) , physical assessment  and other 
tests as per section 6 . 
4.4 Early Withdrawal of Subjects  
4.4.1 When and How to Withdraw S ubjects 
Patients will be withdrawn from the study if any of the following occurs:  
 Disease progression,  
 Intercurrent illness that prevents further administration of treatment,  
 Unacceptable adverse event(s),  
 Patient noncompliance . 
 Patient decides to withdraw from the study  
 General or specific changes in the patient's condition that render the patient unacceptable 
for further treatment in the judgment of the investigator.  
 Initiation of alternative therapy by the treating physician  
 Stem cell transplant prior to completion of 3 cycles of treatment . Of note, stem cell 
collection is allowed a fter 2 or 3 cycles upon discretion of TJU bone marrow transplant 
group and study PI or her designee and patients will continue on the trial until initiation 
of a conditioning regimen and SCT, unless excluded due to other conditions as listed 
above. 
 
After withdrawal from the study further treatment for the subject will be per the discretion of the 
treating physician.  
 
4.4.2 Data Collection and Follow -up for Withdrawn Subjects  
In case of early withdrawal of study, a ttempts will be made to collect data on sub jects who have 
received at  least 1 cycle of treatment. Survival data will be gathered from the treating physician 
of the subject. If a subject withdrew consent  to participate, but allow survival and disease status 
follow up , attempts will be made to record  the data up to the protocol -described end of follow -up 
period. Patients will be followed for dis ease status and survival at Months 3, 6, 9, 12, 18 and 24 
months post treatment or post ASCT with a window of ± 1 month . 
 
5 Study Drug  
5.1 Ofatumumab  
 
Protocol Version 6.3 27 Other Names  : Arzerra™  
Classification  : Antineoplastic Agent, Monoclonal Antibody  
Mode of Action : Ofatumumab is an  anti-CD20 monoclonal antibody and binds specifically to 
both the small and large extracellular loops of the CD20 molecule. The Fab domain of 
ofatumumab binds to the CD20 molecule and the Fc domain mediates immune effector functions 
to result in B -cell lysis in vitro. Data suggest that possible mechanisms of cell lysis include 
complement -dependent cytotoxicity and antibody -dependent, cell -mediated cytotoxicity.  
 
Incompatibilities : Do not mix drug with or administer as an infusion with other medicinal 
products. 
 
Availability:  Novartis will provide Ofatumumab vials presented as either 100mg – acetate 
formulation, 20mg/mL, 5mL fill vials or 1000mg – acetate formulation 20mg/mL, 50mL fill 
vials.  
 
Storage: Refrigerate  between 2° to 8°C (36° to 46°F). Do not free ze. Vials will be protected from 
light. Start infusion within 12 hours of preparation. Discard prepared solution after 24 hours.  
 
Preparation : Prepare all doses in 1,000 mL of 0.9% Sodium Chloride Injection, USP. The solution 
will be a colorless and may c ontain a small amount of visible translucent -to-white, amorphous, 
ofatumumab particles.  
 
Route of Administration:  iv infusion  
 
Pre-medications  
Antiemetics (ondansetron 24 mg IV or equivalent ) will be administered prior to chemotherapy. 
Acetaminophen 650  mg po, diphenhydramine 50 mg po/iv and dexamethasone 20 mg iv (or 
equivalent) will be given within 30 minutes to 2 hours prior to ofatumumab treatment.  If the 2nd 
infusion has been completed without the subject experiencing any Grade 3/4 adverse events 
(AEs), pre-medication with glucocorticoid may be reduced or omitted before the 3rd infusion at 
the discretion of the investigator . 
 
Ofatumumab Infusion  
 
The first dose of ofatumumab will be 300 mg to minimize infusion reactions. The initial rate of 
the first infusion of 300 mg ofatumumab (0.3 mg/mL) will be 12 mL/h. If no infusion reactions 
occur the infusion rate will be increased every 30 minutes, to a maximum of 400 mL/h, 
according to Table below. If this schedule is followed, the infusion duration will be 
approximately 4.6 hours. 
 
Infusion rate at 1st ofatumumab infusion (300 mg)  
Time mL/hour 
0 – 30 minutes  12 
31 – 60 minutes  25 
 
Protocol Version 6.3 28 61 – 90 minutes  50 
91 – 120 minutes  100 
121 - 150 minutes  200 
151 - 180 minutes  300 
181+ minutes  400 
 
If an infusion react ion develops, the infusion will be temporarily slowed or interrupted. Upon 
restart, the infusion rate will be half of the infusion rate at the time the infusion was paused. If, 
however, the infusion rate was 12 mL/hour before the pause, the infusion will be restarted at 12 
mL/hour. Thereafter, the infusion rate may be increased according to the judgment of the 
investigator, in the manner described.  
 
If the previous infusion has been completed without Grade ≥ 3 infusion -associated AEs, the 
subsequent infusio n of the 1000 mg of ofatumumab (1 mg/mL) can start at a rate of 25 mL/hour 
and will be doubled every 30 minutes up to a maximum of 400 mL/h, according to Table 4. 
Duration of the infusion will be approximately 4 hours if this schedule is followed. If the 
previous infusion has been completed with Grade ≥ 3 infusion -associated AEs, the subsequent 
infusion will start at a rate of 12 mL/hour according to Table 2.  
 
Infusion rate at subsequent ofatumumab infusion (1000 mg)  
Time mL/hour  
0 – 30 minutes  25 
31 – 60 minutes  50 
61 – 90 minutes  100 
91 – 120 minutes  200 
121+ minutes  400 
 
During infusion the subject will be monitored closely and appropriate measurements should be 
performed whenever judged necessary.  
 
Side Effects  of Ofatumumab : 
Hematologic:  Neutropenia (≥  Grade 3: 42%; Grade 4: 18%; may be prolonged >2 weeks),  
anemia (16%; Grades 3/4: 5%) . Prolonged (≥1 week) severe neutropenia and thrombocytopenia 
can occur with ofatumumab. Complete blood counts (CBC) and platelet counts will be monitored 
at regular intervals as described  in section 6  
 
Common: (>10% Frequency) : Pneumonia, Upper respiratory tract infection,  bronchitis,  
anemia, cough, dyspnea,  diarrhea, nausea, rash,  pyrexia and fatigue.  Infusion Reactions  
Ofatumumab can cause significant  infusion reactions , including serious. Please see abo ve section 
regarding premedications and ofatumumab infusion.  
 
Occasional : (5-10% Frequency): sinusitis, sepsis, nasopharyngitis, herpes zoster, insomnia, 
headache, hypertension, hypotension, tachycardia, urticaria, hyperhidrosis, back pai n, muscle 
spasms, peripheral edema,  chills. 
 
Rare but S erious (<5% frequency) : 
 
Protocol Version 6.3 29  
Severe Infusion Reactions  
Ofatumumab can cause serious infusion reactions. Please see above section regarding 
premedications and ofatumumab infusion  
 
Progressive Multifocal Leukoencephalopathy  
Progressive multifocal leukoencephalopathy (PML), including fatal PML, can rarely occur with 
ofatumumab . PML diagnosis will be considered in any patient with new onset of changes in pre -
existing neurological signs or symptoms. Ofatumumab will be discontin ued if PML is suspected, 
and subject will be evaluated for PML including consultation with a neurologist, brain MRI, and 
lumbar puncture.  
 
Hepatitis B Infection and Reactivation  
Fulminant and fatal hepatitis B virus (HBV) infection can occur in patients newly exposed to 
HBV following treatment with ofatumumab. Subjects will be  screened for HBV infection before 
initiation of treatment and if positive will be excluded. I f subjects develop Hepatitis B during 
treatment, ofatumumab  will be discontinued and sub jects will be taken off study.  
 
Intestinal Obstruction  
Obstruction of the small intestine was reported in two patients receiving ofatumumab . Subjects 
will have a diagnostic evaluation if obstruction is suspected.  
 
Nursing/Patient Implications :  
Advise pa tients to contact a healthcare professional for any of the following:  
 Signs and symptoms of infusion reactions including fever, chills, rash, or breathing problems 
within 24 hours of infusion  
 Bleeding, easy bruising, petechiae, pallor, worsening weakness , or fatigue  
 Signs of infections including fever and cough  
 New neurological symptoms such as confusion, dizziness or loss of balance, difficulty talking 
or walking, or vision problems  
 Symptoms of hepatitis including worsening fatigue or yellow discolora tion of skin or eyes  
 New or worsening abdominal pain or nausea  
 Pregnancy or nursing  
 Advise patients of the need for:  
 Periodic monitoring for blood counts  
 Avoiding vaccination with live viral vaccines .  
 
Immunizations  
The safety of immunization with  live viral vaccines during or following administration of 
ofatumumab  has not been studied. L ive viral vaccines  will not be administered to subjects within 1 
month of ofatumumab administration .  
 
5.2 Bendamustine  
Other Names : Treanda®  
Classification  : Antineoplastic Agent , Alkylating Agent ; (Nitrogen Mustard)  
 
Protocol Version 6.3 30 Mode of Action : Bendamustine is a bifunctional mechlorethamine derivative containing a 
purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl  
groups. These groups form covalent bonds with electron -rich nucleophilic moieties, resulting in 
interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several 
pathways. Bendamustine  is active against both quiescent and di viding cells. The exact 
mechanism of action  of bendamustine remains unknown  
 
Reconstitution:  Use appropriate precautions for handling and disposal. Reconstitute 25 mg vial 
with 5 mL and 100 mg vial with 20 mL of sterile water for injection to a concentrati on of 5 
mg/mL; powder usually dissolves within 5 minutes. Prior to administration, dilute appropriate 
dose in 500 mL NS (or D 2.51/2NS) to a final concentration of 0.2 -0.6 mg/mL; mix thoroughly.  
 
Storage: 
Bendamustine  may be stored up to 25°C (77°F) with ex cursions permitted up  to 30°C (86°F). 
Retain in original package until time of use to protect from light  
 
Preparation : Bendamustine  will be aseptically reconstituted with Sterile Water for  
Injection, USP per manufacturer’s guidelines.  The volume needed for  the required dose (based 
on 5 mg/mL concentration) will aseptically withdrawn from the vial and transferred to a 500 mL 
infusion bagof 0.9% Sodium Chloride Injection, USP (normal saline), or  a 500 mL infusion  bag 
of 2.5% Dextrose/0.45% Sodium Chloride In jection, USP. The resulting final concentration of 
bendamustine HCl in the infusion bag should be within 0.2 – 0.6 mg/mL. The reconstituted 
solution must be transferred to the infusion bag within 30 minutes of reconstitution.  The 
admixture should be a clea r and colorless to slightly yellow solution.  Any unused solution should 
be discarded according to institutional procedures  for antineoplastics.  
 
Route of Administration:  iv 
 
Contraindications:  Known hypersensitivity (e.g., anaphylactic and anaphylactoid re actions) to 
bendamustine or mannitol.  
 
Availability : Bendamustine hydrochloride for Injection is available commercially and is supplied 
in individual cartons as follows:  
NDC 63459 -390-08 Bendamustine hydrochloride for Injection, 25 mg in 8 mL amber single -use 
vial 
NDC 63459 -391-20 Bendamustine hydrochloride for Injection, 100 mg in 20 mL amber single -
use vial 
 
Drug Interactions: Inhibitors of CYP1A2 may increase plasma concentrations of bendamustine 
and decrease plasma concentrations of active metabolites. Inducers of CYP1A2 may decrease 
plasma concentrations of bendamustine and  increase plasma concentrations of its active 
metabolites. Caution should  be used, if concomitant treatment with CYP1A2 inhibitors or 
inducers is needed . 
 
Side Effects  of Bendamustine   
Common (>20% Frequency) : Nausea, Vomiting, Diarrhea, constipation, fatigue,  fever, 
anorexia, headache, cough . 
 
Protocol Version 6.3 31  
Hematological: leukopenia, neutropenia, lymphopenia, anemia, thrombocytopenia occur in 
majority of patients . 
 
Occasional (5-20% Frequency):  Tachycardia, Stomatitis, abdominal pain, dyspepsia, 
gastroesophageal reflux, dry mouth, abdominal distention, chills, edema, asthenia, infusion site 
pain, pain, herpes zoster infection, upper respiratory infection, sinusitis, pneumonia, febrile 
neutropenia, o ral candidiasis, nasopharyngitis, weight loss, dehydration, hypokalemia, back pain, 
arthralgia , bone pain, pain in extremities , dizziness, dysgeusia, insomnia, anxiety, depression, 
dyspnoea , pharyngolaryngeal pain, wheezing, nasal congestion, rash, pruriti s, dry skin, night 
sweats, hyperhidrosis and  hypotension . 
 
Rare but Serious (< 5% Frequency):  hyperglycemia (3%), elevated creatinine (2%0, 
hyponatremia (2%), hypocalcemia (2%) . Severe hypersensitivity reactions, including Steven -
Johnson syndrome may occu r. 
 
Nursing/Patient Implications :  
1. Allergic (Hypersensitivity) Reactions: Patients will be informed of possibility of severe 
allergic reactions including Steven -Johnson syndrome when the drug is used 
concomitantly with allopurinol and other medications kno wn to cause these syndromes. 
Patients should immediately reports any rash, facial swelling, or difficulty breathing.  
2. Myelosuppression. Monitor CBC. Advice patients of increased risk of infection with 
absolute neutrophil count less than 500 cells/mm³ and in creased risk of bleeding with 
platelet counts less than 20,000 cells/ mm³. Advise patients to call the office if they 
develop a fever above 100.4ºF or notice any easy bruising, petechiae (pinpoint red spots 
on skin), or prolonged bleeding.  
3. Pregnancy and nu rsing. The drug can cause fetal harm. Women who are pregnant or 
become pregnant will be excluded from the study and will be advised to avoid  becoming 
pregnant throughout treatment and for 12 months after treatment. Men receiving the drug 
should use reliabl e contraception for the same time period. Any pregnancy will be 
reported. Nursing mothers will be excluded from study.  
4. Fatigue. Patients will be advised to avoid driving and operating heavy machinery as the 
drug may cause fatigue.  
5. Nausea and Vomiting . Advise patients that the drug may cause nausea and/or vomiting. 
Antiemetics will be administered as indicated.  
6. Diarrhea. Advise patients that the drug may cause diarrhea.  
7. Rash. Advise patients to immediately report severe or worsening rash . 
 
5.3 Etoposide  
Other Names : VP 16  
 
Classification : Podophyllotoxin derivative, topoisomerase II inhibitor  
 
Mode of Action : Two different dose -dependent responses are seen. At high concentrations (10 
mcg/mL or more), lysis of cells entering mitosis is observed. At low conce ntrations (0.3 to 10 
mcg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular 
 
Protocol Version 6.3 32 assembly. The predominant macromolecular effect of etoposide appears to be DNA synthesis 
inhibition.  
 
Storage and Stability : Store at controll ed room temperature 15° to 30°C.  Unopened vials are 
stable for 24 months at room temperature (25°C). Vials diluted as recommended to a 
concentration of 0.2 to 0.4 mg/mL are stable for 96 and 24 hours, respectively, at room 
temperature (25° C) under normal  room fluorescent light in both glass and plastic containers.  
 
Preparation : Etoposide Injection will be diluted with either 5% Dextrose Injection, USP or 0.9% 
Sodium Chloride Injection, USP to give a final concentration of 0.2 to 0.4 mg/mL.  
 
Route of Admin istration: i.v 
 
Availability : Etoposide is available  commercially  for intravenous use as a sterile 20 mg/mL 
solution in 5 mL,  25 mL, or 50 mL sterile multiple dose vials. Each mL contains 20 mg 
Etoposide. Etoposide Injection 20 mg/mL is supplied as follows : 
NDC Number Size  
0703-5643-01 100 mg 5 mL Multiple Dose Vials  
0703-5643-03 100 mg 5 mL Multiple Dose Vials  
0703-5646-01 500 mg 25 mL Multiple Dose Vials  
0703-5646-03 500 mg 25 mL Multiple Dose Vials  
Also available as:  
0703-5667-01 1 gram 50 mL Multiple Do se Vials 
5 mL and 25 mL vials are available individually or packaged 10 per shelfpack.  
50 mL vials are individualy packaged.  
 
Side Effects of Etoposide  
Common (>20% frequency) : Alopecia (8% to 66%), Nausea/vomiting (31% to 43%), 
Leukopenia (60% to 91%; Grade 4: 3% to 17%; nadir: 7 -14 days; recovery: by day 20), 
thrombocytopenia (22% to 41%; Grades 3/4: 1% to 20%; nadir 9 -16 days; recovery: by day 20), 
anemia (≤33%).  
 
Occasional (5-20% frequency):  anorexia (10% to 13%), diarrhea (1% to 13%)  
 
Rare but Serious  (< 5% Frequency):  Hypotension (1% to 2%; due to rapid infusion), 
Stomatitis (1% to 6%), abdominal pain (up to 2%), Hepatic toxicity (up to 3%), Peripheral 
neuropathy (1% to 2%), Anaphylactic -like reaction (I.V. infusion 1% to 2%; oral capsules <1%; 
including chills, fever, tachycardia, bronchospasm, dyspnea).  
 
<1% (Limited to important or life -threatening ): Amenorrhea, blindness (transient/cortical), 
cyanosis, extravasation (induration/necrosis), facial swelling, hypersensitivity, hypersensitivity -
associated apnea, interstitial pneumonitis, laryngospasm, maculopapular rash, metabolic 
acidosis, MI, mucositis, optic neuritis, perivasculitis, pruritus, pulmonary fibrosis, radiation -
recall dermatitis, rash, seizure, Stevens -Johnson syndrome, tongue swelling, to xic epidermal 
necrolysis weakness.  
 
 
Protocol Version 6.3 33 5.4 Carboplatin  
Classification : Platinum analog  
 
Mode of Action : Produces predominantly interstrand DNA cross -links rather than DNA -protein 
cross-links. 
 
Storage and Stability:  Unopened vials of carboplatin injection ar e stable for the life indicated on 
the package when stored at 20° to 25°C (68° to 77°F).   Protect from light.  
 
Dose Specifics : Doses will be calculated by the target AUC using the Calvert formula, where 
Total dose (mg) = Target AUC x (GFR + 25) . If estimat ing glomerular filtration rate (GFR) 
instead of a measured GFR, the GFR will be capped at a maximum of 125 mL/minute to avoid 
potential toxicity. In this study an AUC of 5 will be used for carboplatin dosing.   
 
Preparation : Carboplatin injection is a premi xed aqueous solution of 10 mg/mL . 
Carboplatin injection can be further diluted to concentrations as low as 0.5 mg/mL with 5% 
Dextrose in Water (D5W) or 0.9% Sodium Chloride Injection.  When prepared as directed, 
carboplatin injection is stable for 8 hours a t room temperature 25°C (77°F). I t is recommended 
that carboplatin injection be discarded 8 hours after dilution.  
 
Route of Administration : iv 
 
Compatibility:  Stable in D 5 1/4NS, D5 1/2NS, D5NS, D5W, NS.  
 
Availability : Carboplatin Injection, 10 mg/mL, is available commercially and is supplied as 
follows: 
NDC 55390 -153-01, 50 mg/5 mL aqueous solution in multidose vials, individually boxed.  
NDC 55390 -154-01, 150 mg/15 mL aqueous solution in multidose vials, individually boxed.  
NDC 55390 -155-01, 450 mg/45 mL aqueous solution in multidose vials, individually boxed.  
 
Side Effects  of Carboplatin   
Common (>20% frequency):  Pain (23%), Hyponatremia (29% to 47%), hypomagnesemia 
(29% to 43%), hypocalcemia(22% to 31%), hypokalemia (20% to 28%), Vomiting (65% to 
81%), Myelosuppression (dose related and dose limiting; nadir at ~21 days; recovery by ~28 
days), anemia (71% to 90%; Grades 3/4: 21%), leukopenia (85%; Grades 3/4: 15% to 26%), 
neutropenia (67%; Grades 3/4: 16% to 21%), thrombocytopenia (62%; Grades 3/4: 25% to 35%), 
Alkaline phosphatase increased (24% to 37%), AST increased (15% to 19%) , Creatinine 
clearance decreased (27%), BUN increased (14% to 22%)  
 
Occasional (5-20% Frequency):  abdominal pain (17%), nausea (without vomiting: 10% to 
15%), Weakness (11%), Hype rsensitivity/allergic reaction (2% to 16%), Neurotoxicity (5%), 
Constipation (6%), diarrhea (6%), Bleeding (5%), hemorrhagic complications (5%), Bilirubin 
increased (5%), Peripheral neuropathy (4% to 6%), Creatinine increased (6% to 10%), Infection 
(5%). 
Rare but Serious (< 5% Frequency):  Alopecia (2% to 3%), stomatitis/mucositis (1%), taste 
 
Protocol Version 6.3 34 dysgeusia (1%), Visual disturbance (1%), Ototoxicity (1%).  
 
<1% (Limited to important or life -threatening):  Anaphylactic reaction, bronchospasm, 
cardiac failure, cerebr ovascular accident, dehydration, embolism, erythema, hemolytic uremic 
syndrome (HUS), hyper -/hypotension, injection site reactions (pain, redness, swelling), necrosis 
(associated with extravasation), neutropenic fever, pruritus, rash, secondary malignancie s, 
urticaria, vision loss .  
 
Contraindications  
History of severe allergic reaction to cisplatin, carboplatin, other platinum -containing 
formulations, mannitol, or an y component of the formulation.  
 
5.5 Treatment R egimen 
5.5.1 Chemotherapy R egimen 
Agent Dose Route Infusion 
duration Schedule  
Ofatumumab  Cycle 1: 300 mg  on day 
1 (or up to 3 days prior 
to day 1), 1000 mg on 
day 3.  
Cycles 2 and 3:  1000 
mg on day 1.  IV  Per section 
5.1 Cycle 1: 
Days 1 and 
3. Cycle 2 
and 3: Day 1.  
Bendamustine  Phase I: per the dose 
level. 
Phase II: MTD 
achieved in Phase I  IV  30 minutes  Days 1and 2 
Carboplatin  AUC 5 IV  1 hour Day 2 
Etoposide  100 mg/m²  IV 1 hour Day 1-3 
 
Cycles will be repeated  approximately every 3 weeks or  when counts recover , whichever is later . 
Count rec overy is defined as ANC >1 000/ μl, Platelets > 50,000/ μl. 
 
The patients will  be admitted to Thomas Jefferson University (TJU) hospital and treated as 
inpatient for the first cycle. If no unexpected Grade ≥3 toxicities occur during infusion of the 
first cycle all subsequent treatments will be administer ed in the outpatient infusion center of 
Kimmel Cancer Center of TJU  or as inpatient  at TJUH, as per discretion of the treating physician  
 
5.5.2 Supportive C are: 
5.5.2.1 Pre-medications  
Antiemetics (ondansetro n 24 mg IV or equivalent ) will be administered prior to chemotherapy.  
Acetaminophen 650 mg po, diphenhydramine 50 mg po/iv and dexamethasone 20 mg iv (or 
equivalent) will be given within 30 minutes to 2 hours prior to ofatumumab treatment.  If the 2nd 
infusion has been completed without the subject experiencing any Grade 3/4 adverse events 
(AEs), pre -medication with glucocorticoid may be reduced or omitted before the 3rd infusion at 
the discretion of the investigator . 
 
 
Protocol Version 6.3 35  
5.5.2.2 Ofatumumab Infusion  
Will be infused as per Novartis protocol.  See section 5.1.  
 
5.5.2.3 Tumor Lysis Prophylaxis  
All patients will receive allopurinol 300 md PO daily starting at least 24 hours prior to the 
initiation of the first cycle of therapy or the day of therapy and continued fo r at least the first 
week of the initial cycle of therapy. In case of an allergic reaction to allopurinol tumor lysis 
prophylaxis will include aggressive IV hydration and close monitoring of tumor lysis markers. 
Rasburicase may be administered as per discr etion of the treating physician. For all patients 
additional measures will include aggressive IV hydration and rasburicase administration at the 
discretion of the treating physician. Patients will also be assessed for laboratory markers of 
tumor lysis synd rome. 
 
5.5.2.4 Growth Factor S upport 
A granulocyte colony stimulating factor (either filgrastim or peg -filgrastim) is mandatory and 
will be administered at least 24 hours but not later than 96 hours after completion  of each cycle  
of chemotherapy . 
 
5.5.2.5 Prophylaxis of Pneumocystis jirovecii (previously known as Pneumocystis carinii)  
It is recommended that patients receive  prophylaxis for Pneumocystis during chemotherapy  of 
Trimethoprim /sulfamethoxazole 1 DS PO daily or 2 DS tablets PO Monday, Wednesday, Friday. 
Patients allergic to the drug may receive Dapsone  100 mg/day  or Pentamidine at the discretion of 
the treating physician . 
 
5.5.2.6 Anti-Fungal Prophylaxis   
It is recommended that patients receive anti fungal prophylaxis with fluconazole 400 mg daily  or 
per the discretion of the treating physician.  
 
5.5.2.7 Antiviral P rophylaxis  
Patients may be given anti viral prophylaxis with acyclovir 400 mg twice daily or per the 
discretion of the treating physician.  
 
5.5.2.8 Prophylaxis of CNS D isease 
Prophylaxis  of CNS disease using intrathecal dosing of cytotoxic regimens is permitted but not 
required by protocol and should be performed according to the discretion of the treating 
physician and/or study PI or her designee.  
 
5.6 Method for Assigning Subjects to Tr eatment Groups  
This is an open label study of a single therapy regimen.  
 
5.7 Preparation and Administration of Study Drug  
Ofatumumab  will be delivered to the Investigational Drug Service at TJUH from Novartis. The 
Investigational Drug Service will then provide  the doses in the i npatient and outpatient oncology 
infusion setting per the treatment schedule ( Cycle 1:Days 1 and 3. Cycle 2 and 3: Day 1 ). 
Bendamustine, carboplatin and etoposide will be obtained commercially by the qualified 
 
Protocol Version 6.3 36 personnel who are familiar with procedures that minimize undue exposure to them and to the 
environment should undertake the preparation, handling, and safe disposal of chemotherapeutic 
agents in an appropriate environment.  
Discard unused portions of injectable chemotherapeutic agent s that do not contain a 
bacteriostatic agent or are prepared with unpreserved diluents (i.e., Sterile Water for Injection 
USP or 0.9% Sodium Chloride for Injection USP) within eight hours of vial entry to minimize 
the risk of bacterial contamination.  
 
The total administered dose of chemotherapy may be rounded up or down within a range of 5% 
of the actual calculated dose.  
 
5.8 Subject Compliance Monitoring  
Only dose delays or modifications by the investigators or treating physician are permissible.  
 
5.9 Prior and Concomitant Therapy  
1. Information of prior cytotoxic regimens will be collected.   
2. All concomitant medical therapy will be collected as part of the history.   
3. All concomitant medicines/therapies are permitted during the study except for those 
noted in the exclusion criteria in section 4.2.  
  
5.10 Receiving, Storage, Dispensing and Return  
5.10.1 Receipt of Drug Supplies  
Ofatumumab will be supplied by Novartis to the Investigational  Drug Service  (IDS) at Thomas 
Jefferson University hospital.  Upon receipt of the study treatment supplies, an inventory must be 
performed and a drug receipt log filled out and signed by the person accepting the shipment. It is 
important that the designated study staff counts and verifies that the shipment contains all the 
items noted in the shipment inventory. Any damaged or unusable study drug in a given shipment 
(active drug or comparator) will be documented in the study files. The investigator must notify 
study sponsor of any damaged or unusable study treatments that were supp lied to the 
investigator’s site.  
 
5.10.2 Storage  
See section 5.1 through 5.4  
 
5.10.3 Dispensing of Study Drug  
Ofatumumab will be dispensed by the IDS pharmacy;  all other drugs, pre -meds, etc will come 
from commercial supply from the regular pharmacy.  Regular study drug reconciliation will be 
performed to document drug assigned, drug administered , and drug remaining. For ofatumumab,  
this reconciliation will be logged by the Investigational Drug Service on the drug reconciliation 
form. 
 
5.10.4 Return or Destr uction of Study Drug  
At the completion of the study, there will be a final reconciliation of drug shipped, drug 
consumed, and drug remaining. This reconciliation will be logged on the drug reconciliation 
form, signed and dated. Any discrepancies  noted will  be investigated, resolved, and documented 
prior to return or destruction of unused study drug . Drug destroyed on site will be documented in 
 
Protocol Version 6.3 37 the study files . The remaining drug will be shipped back to the supplier. If the supplier requests 
that the drug be  destroyed on site, it will be documented in the study files.  
 
6 Study Procedures  
6.1 Schema  
Prior to enrollment (within 28 days)  each eligible subject will have a detailed medical history, 
comprehensive physical examination, vital signs and baseline laborat ory parameters (including 
CBC, CMP  (including liver function tests, kidney function tests, electrolytes) , Uric acid, LDH, 
Hepatitis B&C screen, HIV screen, IgG,  IgM and IgA. Based on these and a pathological review 
of initial diagnostic biopsy , subjects wi ll be evaluated for study eligibility. Serum pregnancy test 
will be done if applicable in eligible subjects at the time of study enrollment. We will attempt to 
get a repeat lymph node/mass /bone marrow biopsy of a site involved at the time of relapse t o 
confirm the diagnosis  and for correlative studies . If another biopsy is unobtainable, either due to 
location of disease, risk of procedure or patient preference , the diagnosis will be confirmed on 
the basis of initial diagnostic pathology.  
 
See Appendix 4 for  Study Procedure s Schedule.  
 
Pathology Review  
If diagnostic biopsy was performed at another institution i t is required that diagnostic material 
from the original tumor biopsy must be submitted to TJU hemato -pathology for review and 
classification.  
 
Protocol Deviations  
Protocol coordinator must be notified of any deviations to protocol.   
Any deviations to protocol or unanticipated problems to be reported to the IRB via an OHR -20. 
 
6.2. Stem Cell Mobilization  and Stem Cell Transplant  
This section is relevan t to potential transplant candidates.  
 
Mobilization of stem cells will be performed after Cycle 2 or Cycle 3 upon discretion of TJU 
hematopoietic stem cell transplant group and in agreement with the study PI or her designee  
from the key study personnel . Stem cells will be mobilized according to TJU hematopoietic stem 
cell transplant  group policy using filgrastim, pegfilgrastim or/and prelixafor (Mozobil). Use of 
other agents for mobilization may be approved following  consultation with the study PI or her 
designee.  
 
Restaging CT scan should be performed after Cycle 2 and prior to stem cell mobilization and 
restaging whole body PET/CT scan should be performed after Cycle 3; it should be performed 
after Cycle 2 if patient is proceeding to autologous SCT  after 2 cycles of the study regimen (see 
section 6).  
 
A patient may proceed to high dose chemotherapy and autologous SCT after 2 cycles of BOCE 
trial or a third cycle of BOCE regimen may be given after stem cell collection and before 
autologous SCT upon discre tion of TJU hematopoietic stem cell transplant group and in 
agreement with the study PI or her designee. Stem cell collection should be completed within 8 
 
Protocol Version 6.3 38 weeks following Cycle 2 in order to proceed to Cycle 3. A whole body PET/CT scan will be 
performed in  addition to CT scan  or MRI if patient is proceeding to autologous SCT after 2 
cycles. 
 
Allogeneic stem cell transplant will be performed in selected cases upon discretion of TJU 
hematopoietic stem cell transplant group and in agreement with the study PI o r her designee.     
 
If restaging studies after 2 cycles and before stem cell mobilization reveal progressive disease the 
patient will be withdrawn from the study and no stem cell collection will be attempted at that 
point.         
 
6.3. Dose Delays and Do se Reductions  
6.3.1 Cycle Delays  
Cycles should typically be administered at 3 week intervals. Minor variations, up to 3 days, are 
permissible for logistical reasons; longer delays, up to 8 weeks are allowed for cytopenias, Grade 
≥3 AEs or for stem cell mobilization. Subjects will be withdrawn if dosing is delayed for more 
than 8 weeks due to an AE. Dose reductions may be approved following consultation with the 
protocol coordinator and study PI or her designee.  
 
Administratio n of Cycle 2 or 3 of the investigational regimen will be delayed if the absolute 
neutrophil count is <1.0x109/L or the platelet count is <50x 109/L. However, for subjects with  
counts below these levels at baseline , the start of Cycles 2 and 3 should be delayed until 
neutrophil and platelet counts have recovered to 80% of the baseline values. A granulocyte 
colony stimulating factor (either filgrastim or pegfilgrastim) is recommended at least 24 hours 
but not later than 96 hours after completion of each cycle of chemotherapy.  
 
It is recognized that occasionally mild neutropenia (ANC 0.5 -1,0x 109/L) may persist in some 
responding patients in whom further delay in administering treatment is not medically 
appropriate .  Such patients whose counts do not further imp rove following a  1-2 week delay may 
receive the next cycle of therapy after conferring with the PI (or h er designee).  
 
6.3.2 Dose Reduction of Bendamustine  
In case of  Grade 4 infection, or Grade ≥ 3 non-hematologic toxicity that persists for 7 days or 
more, dose of bendamustine should be reduced with the following cycle of chemotherapy 
according to the following schema: 
 
 
 
 
 
 
6.3.3 Dose Modifications of Carbop latin, Etoposide and Ofatumumab  
Dose reductions of carboplatin and etoposide  should be avoided but , if medically appropriate , a 
25% dose reduction  may be approved following consultation with the PI of the study  or with her 
designee.  
 Initial dose  Decrease dose to:  
120 mg/m² 90 mg/m² 
  90 mg/m² 70 mg/m² 
  70 mg/m² 50 mg/m² 
  50 mg/m² Withdraw from the study  
 
Protocol Version 6.3 39 There is no dose reduction for Ofatumumab, only infusion rate adjustment or discontinuation.  
 
Liver Chemistry Interruption/Stopping Criteria  (see section 8.4 for more information).  
The sponsor-investigator is to review all events which meet liver chemistry stopping criteria to 
determine if the event was due to ; 
 tumor lysis, disease related liver involvement  
 concomitant chemotherapy  
 other identified cause and to exclude drug induced liv er injury (DILI) due to 
Ofatumumab  
 
If the event is determined to be due to causes other than Ofatumumab DILI and improvement is 
observed after withdrawal of Ofatumumab, rechallenge may be attempted if deemed appropriate 
by the sponsor -investigator and in addition to consent of the subject .  
 
6.4. Disease Response  
Response Criteria  
Baseline imaging studies such as CT scans of the thorax, abdomen and pelvis  or MRI (may 
include other sites, such as head, nec k or extremities , if clinically indicated ) and the whole body 
PETCT will be performed prior to the start of study therapy.  If at any time point starting from 
month 3 post chemotherapy,  a problem occurs with precertification of a particular PET/CT scan 
(documentation is  required for each time point), a dia gnostic quality CT scan (as described 
above) or/and MRI (if done at baseline), are accepta ble for restaging purposes . Patients wil l be 
assessed for response based on the revised response criteria by  the Revised Response  
Criteria for Malignant Lymphoma [Che son, 2007]  (see appendix 5)  incorporating  CT scans of 
the thorax, abdomen and pelvis  and whole body  PET/CT (3 3). Response will be first assessed 
after 2 cycles using CT scan or/and MRI (if relapse was confirmed by MRI before treatment). 
Restaging studies w ill be performed 2 -8 weeks after Cycle 2 but before Cycle 3. Restaging 
PET/CT scan will be performed after 3 cycles of treatment  (3-8 weeks post treatment  but before 
high dose chemotherapy and ASCT, if applicable ). Additional studies, such as CT scan of chest, 
abdomen and pelvis ( or MRI) will be performed after 3 cycles upon discretion of treating 
physician  or study PI . Imaging may be submitted for retrospective review.  
 
Bone marrow biopsies will be repeated after completion of 3 cycles or before stem cell 
mobilization if they were abnormal before treatment.  
 
PET/CT Scans 
The International Working Group (IWG) recommends the use of pretreatment PET with a low 
resolution CT ( PETCT) scan in evaluation of patients with DLBCL and other aggressive 
lymphomas when r esponse rate is a major end point  (33). Thus in the current study we will 
assess patients with PETCT pretreatment and post treatment if initial PETCT was positive. Post 
treatment PETCT will be performed 3-8 weeks after completion of therapy.  Of note, the C T 
portion of PET /CT should not be counted as diagnostic CT scan and a high resolution CT scan or 
MRI should be done in addition to PET /CT when required by protocol (see Appendix 4: Study 
Procedures Schedule ). Follow up PET/CT scans will be done  per institu tional guidelines post 
treatment or post transplant.  A diagnostic quality, contrast enhanced CT scan of the chest, 
abdomen and pelvis (and neck, if done at baseline or if a new suspected area of involvement) 
 
Protocol Version 6.3 40 or/and MRI of any site can be added at any resta ging time point upon discretion of the study PI, a 
co-investigator or a treating physician . If at any time point starting from month 3 post 
chemotherapy,  a problem occurs with precertification of a particular PET/CT scan 
(documentation is required for each time point ), a diagnostic quality CT scan ( as described 
above) or/and MRI ( if done at baseline ), are accepta ble for restaging purposes.   
 
Response Evaluation for Transplant C andidates  
 Restaging CT scan (or/and MRI if positive before treatment) should be performed after Cycle 2 
and prior to stem cell mobilization and restaging PET /CT scan should be performed after Cycle 3 
(see section 6). A patient may proceed to high dose chemotherapy and ASCT after 2 cycles of 
BOCE trial or a third cycle of BOCE regime nt may be given after stem cell collection and before 
ASCT upon discretion of TJU hematopoietic stem cell  transplant group and in agreement with 
the study PI or her designee. Stem cell collection should be completed within 8 weeks following 
Cycle 2 in orde r to proceed to Cycle 3. A PET /CT scan should be performed in addition to CT 
scan or/and MRI if patient is proceeding to ASCT after 2 cycles  
 
6.5 Correlative S tudies 
6.5.1 Flow Cytometry for CD20 E xpression  
CD20 expression will be assessed by flow cytometr y as per standard protocol on fresh tissue 
biopsy, if available . If bone marrow is involved, or if there are circulating lymphoma cells in 
peripheral  blood flow cytometry analysis for CD20 will be also performed  on aspirated bone 
marrow or peripheral blood  cells (if available) . The intensity of CD20 expression will be 
determined in 3 levels in reference to negative isotope controls: Strongly positive: significant 
shift of abnormal cell population from negative control with no overlap of two populations. 
Weakly positive: shift of abnormal cell population from negative control but overlap is present. 
Negative: no significant shift of abnormal population from negative control.   
 
6.5.2 Immunohistochemistry ( IHC) Studies 
Various panels of IHC will be performed ba sed on disease type. The following antibodies will be 
performed on all available tissue samples : CD20, CD3, Ki -67. Additional selected antibodies 
including CD5, CD10, CD23, BCL1, BCL2, BCL6, and MUM1 will be performed according to 
specific disease type. CD20 expression will be assessed on paraffin sections by IHC in all 
available tissue Three levels of CD20 expression intensity are determined using light 
microscopy : strongly positive, weakly positive  or negative. 
 
6.5.3 FISH S tudies 
Fluorescence in situ hyb ridization (FISH) will be performed on formalin fixed, paraffin 
embedded tissue  or/and on touch-preps, if available . The panel selection is based on specific 
disease type :  
Diffuse large B -cell lymphoma     BCL2, BCL6, cMYC 
Mantle Cell Lymphoma                BCL1 (also cMYC for blastoid variant)  
Transformed lymphoma                BCL2, BCL6, cMYC 
 
6.5.4 Analysis of Epstein Barr Encoded RNA (EBER)   
Presence of Epstein Barr virus  will be assessed using in situ hybridization for Epstein Barr 
Encoded RNA (EBER)  on tumor tissue sections in all available tissue samples.  
 
Protocol Version 6.3 41  
 
6.5.5 Submission of Blood and Bone Marrow S amples 
In the consent section, subjects will be asked if they are willing to participate in correlative 
studies. Tissues from the subjects who answer “Y es” to “I allow my blood or bone marrow to be 
tested for additional laboratory research studies as a part of the clinical trial” will be utilized for 
correlative studies.  Of note, blood samples will be collected for correlative studies only if 
suspected ci rculating lymphoma cells, based on routine CBC studies or flow cytometry data.  
 
6.5.6 Freezing and S torage 
After adequate tissue has been utilized for the correlative studies, the remained of the fresh tissue 
(lymph node tissue, bone marrow or other tissu e obtained for diagnostic purposes and correlative 
studies) will be frozen and stored to be utilized for additional tests as per study protocol or for 
future IRB approved studies. Subjects will be asked if they allow  storage and  future use of their 
tissue for research purposes. If they refuse, the remained of tissue will not be stored and utilized 
for future studies.  See Appendix 3. 
 
6.6 Duration of Therapy  
Treatment may continue for 3 cycles or until one of the following criteria applies:  
 Stem Cell Transpl ant after 2 cycles of the study regimen  
 Disease progression,  
 Intercurrent illness that prevents further administration of treatment,  
 Unacceptable adverse event(s),  
 Patient decides to withdraw from the study, or  
 General or specific changes in the patient's condition render the patient unacceptable for 
further treatment in the judgment of the investigator.  
 
6.7 Duration of Follow Up  
 
Patients will be followed for dis ease status and survival at  3, 6, 9, 12, 18 and 24 months  (with a 
window of ± 1 month ) post treatment, post ASCT ,  removal from  the study, or until death, 
whichever occurs first.  Patients removed from  the study for unacceptable adverse event (s) will 
have AE(s) followed until resolution or stabilization.  
 
6.8 Follow up/monitoring  
 
After completion  of treatment, patients will be followed at a minimum of every 3 months with a 
window of +/- 1 month) for the first year and then at  least every 6 months for the second year. 
Patient will be seen and examined by their treating physician along  with a resear ch nurse. 
Imaging studies per protocol will be obtained  (see Appendix 4: Study Procedures Schedule ). 
Whenever possible, the monitoring will occur as part of the routine follow -up visit. 
 
7 Statistical Plan  
7.1 Sample Size Determination  
A total of 9 to 18 p atients will be enrolled in Phase I part of the trial. Twenty four patients will be 
enrolled in Phase II part of the trial. This is based on the Simon Optimal Two -Stage Design with 
 
Protocol Version 6.3 42 the assumption that a n ORR rate of 25% indicates that the treatment is not effective and an ORR 
rate of 50% indicates that the treatment is effective with alpha (type I error) 0.05 and 80% 
power. The last 6 patients enrolled at the MTD level in Phase I will be included in the Phase II 
part of the study. Thus the estimated maximum  sample size will be 36  patients. 
 
7.2 Statistical M ethods 
Phase I Design  
In Phase I, three doses and 3 -6 subjects per dose with the total of 9 -18 subjects will be studied 
(please see the study design table below). We will use a two -stage accrual design at  each dose 
considered. We will initially enter 3 subjects at each dose. If none of the three experiences a 
dose-limiting toxicity we will proceed to the next dose. If one of the three experiences a dose-
limiting toxicity, we will accrue 3 more subjects at that dose. If at any time there are two or more 
dose-limiting toxicities (in the 3 -6 subjects) on a given dose, dose escalation will be stopped. 
This dose level will be declared the maximally administered dose (highest dose administered). 
Three (3) additio nal patients will be entered at the next lowest dose level if only 3 patients were 
treated previously at that dose. If >2 DLT at ( -1) dose level, the study will be terminated.  No 
patient will be treated at a higher dose until the 3 or 6 patients have compl eted their toxicity 
evaluation period at the current dose. With this plan, a dose with a 50% or greater probability of 
causing a dose -limiting toxicity has at most a 12.5% chance of satisfying the conditions for dose 
escalation after the first 3 subjects a nd at least a 50% chance of stopping at 3. With the two -
stages (3-6) together, there is at most a 17.2% chance of escalation. The MTD will then be the 
last dose studied or the previous dose, based on clinical judgment of the degree of toxicity seen 
at the last dose. While waiting for the 3 or 6 subjects accrued according to plan to complete their 
toxicity evaluation period, additional subjects may be accrued at the current dose. These 
additional subjects will not count towards the formal plan of stopping at  two or more toxicity 
occurrences, but will contribute to the judgment as to the MTD.  For determination of Dose 
Limiting Toxicity please see section 8. 1 
 
Number of Patients with 
DLT at a Given Dose Level  Escalation Decision Rule  
0 out of 3  Enter 3 patient s at the next dose level.  
>2 Dose escalation will be stopped. This 
dose level will be declared the 
maximally administered dose (highest 
dose administered). Three (3) 
additional patients will be entered at the 
next lowest dose level if only 3 patients 
were treated previously at that dose.  If 
>2 DLT at (-1) dose level, the study 
will be terminated.  
1 out of 3  Enter at least 3 more patients at this 
dose level.  
 If 0 of these 3 additional patients 
experience DLT, proceed to the next 
 
Protocol Version 6.3 43 dose level.  
 If 1 or more of  the 3 additional 
patients suffer DLT, then dose 
escalation is stopped, and this dose is 
declared the maximally administered 
dose. Three (3) additional patients 
will be entered at the next lowest 
dose level if only 3 patients were 
treated previously at tha t dose. 
<1 out of 6 at highest dose 
level below the maximally 
administered dose  This will be the recommended phase 2 
dose. At least 6 patients must be 
entered at the recommended phase 2 
dose. 
 
Phase I Data Analyses  
Data analysis of phase I studies is des criptive. At each dose level DLT will be assessed during a 
minimum of one cycle period. A dose escalation will be allowed only when all 3 or 6 patients 
have completed at least one cycle of the studied regimen. All estimates of dose -specific rates 
(e.g., response and toxicity) will be presented with corresponding confidence intervals using the 
exact method. The method of Atkinson and Brown will be used for any rate related to definition 
of dose limiting toxicity, due to two -stage sampling. The method of Cono ver will be used 
otherwise . 
 
After all the patients have been accrued to  the Phase I part of the study, the study investigators 
and sponsor will convene to assess safety and toxicity. If there are concerns over the safety of the 
combination therapy, the in vestigator s and the sponsor may terminate the study. Also, if there are 
>2 DLT at ( -1) dose level during accrual period, the study will be terminated.  
 
Phase II Design and Sample Size  
We design this trial with the potential for early termination in the cas e of a poor ORR rate. The 
design will be a two -stage design using the approach of Simon, selecting among admissible 
choices (Jung et al.). Choice of design is guided by a desire to stop the trial early if the actual 
ORR rate is 25% or less. If the ORR rate  is 50% or greater, we would like to have a low 
probability of failing to conclude effective.   
 
Since the Phase I subjects will be treated and followed the same as the Phase II subjects, the 
Phase I subjects (6) accrued at the chosen MTD will be considere d as accrued to the Phase II 
study as well.  
 
Our chosen design is:  
Look after this number of patients : Stop if number of successes is less than: 
9 3 
24 10 
 
After testing the treatment on 9 patients in the first stage, the trial will be terminated if 2 or fewer 
respond. After the first 9 patients have been accrued the trial will be on hold for a response 
 
Protocol Version 6.3 44 analysis. Once there are confirmed 3 or more responses (PR or CR) the accrual will continue. 
The trial will be terminated if less than 3 responses were achieved among first 9 accrued patients.  
If the trial goes on to the second stage, a total of 24 patients will be studied. If the total number 
responding is less than or equal to 9, the treatment is rejected.  
 
With this design, we have no more than a 20% chance of concluding ineffective ( 25% ORR 
rate) when the ORR rate is at least 50%.  Similarly, we have no more than a 5% chance of 
concluding effective ( 50% ORR rate) when it is ineffective.  If the actual ORR rate is 25% or 
worse, we have at least a 0.6 0 probability that the trial will stop after the first 9 subjects. Phase II 
design requires a maximum of 24 patients. Thus, including 6 patients from Phase I at MTD with 
Phase II patients, the total of 30 to 36 patients is required for combined Phase I/II study. 
 
7.3 Subject P opulation(s) for  Analysis  
All patients who were enrolled in the study and received any clinical trial material will be 
included in the intent -to-treat analysis. All safety analyses will be performed on the intent -to 
treat population . The efficacy analysis will include any patient who has  received at least one dose 
of the investigational drug Ofatumumab . All estimates of rates (e.g., response and toxicity)  will 
be presented with corresponding confidence intervals. For ORR rates, the met hod of Atkinson 
and Brown will be used to allow for the two -stage design; otherwise the method of Conover will 
be used. 
 
7.4 Analysis of Missing D ata 
Subjects with unknown or missing responses will be considered as non -responders.  
For endpoints which dete rmine the percentage of responders, subjects with unknown or missing 
response will be assumed to be non -responders, and will be included in the denominator when 
calculating the percentages.  
 
8.0 Safety and Adverse Events  
8.1 Definitions  
Adverse Event  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in 
severity during the course of the study. Intercurrent illnesses or injuries will be regarded as 
adverse events. Abnormal results of diagnostic procedures are considere d to be adverse events if 
the abnormality:  
 results in study withdrawal  
 is associated with a serious adverse event  
 is associated with clinical signs or symptoms  
 leads to additional treatment or to further diagnostic tests  
 is considered by the investigator t o be of clinical significance  
 
Serious Adverse Event  
Adverse events are classified as serious or non -serious.   
 
A serious adverse event  is any AE that is:  
 fatal 
 life-threatening  
 
Protocol Version 6.3 45  requires or prolongs hospital stay  
 results in persistent or significant disa bility or incapacity  
 a congenital anomaly or birth defect  
 an important medical event  
 
Important medical events are those that may not be immediately life threatening, but are clearly 
of major clinical significance. They may jeopardize the subject, and may require intervention to 
prevent one of the other serious outcomes noted above. For example, drug overdose or abuse, a 
seizure that did not result in in -patient hospitalization, or intensive treatment of bronchospasm in 
an emergency department would typical ly be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-
serious adverse events .  
 
Toxicity will be evaluated according to the NCI Common Terminology Criteria for Adverse 
Events Version 4.0 e xcept for hematologic toxicity . 
 
Hematologic toxicity will be assessed using the NCI working group grading scale as proposed by 
Hallek et al (34). Hematologic toxicity is expected and a grade of cytopenia will be recorded but 
it is not a dose limiting toxi city in this study . Grade 3 and 4 neutropenia , grade 3 and 4 
thrombocytopenia and Grade 4 anemia are expected desirable targets and should not be 
considered SAEs in this trial. Only clinically significant events such as neutropenic fever will be 
captured a s an SAE; similarly, grade 4 thrombocytopenia, complicated by bleeding is a 
reportable even t. In terms of cytopenias, only persistent grade 4 neutropenia or/and 
thrombocytopenia lasting longer than four weeks as measured by twice weekly CBC 
measurements wi ll be considered an SAE.  
 
Dose-Limiting Toxicity (DLT) 
DLT will  be graded according to the National Cancer Institute Common Terminology Criteria 
(NCI CTCAE, Version 4.0). DLT will be defined as any Grade 4 infection, or Grade ≥ 3 non-
hematologic toxicity t hat persists for 7 days or more. Inability to restart therapy in greater than 8 
weeks after previous cycle due to investigational agent -related toxicity or a delayed count 
recovery will be considered dose limiting. Toxicity must be considered related or po ssibly 
related to study drug in order to be classified as a DLT or treatment -related Grade 3 or greater 
toxicity. 
The following adverse events will NOT be considered dose limiting:  
 anemia 
 thrombocytopenia  
 neutropenia  
 Alopecia 
 Nausea, vomiting, anorexia  
 Grade 3 fatigue resolving before the next scheduled dose  
 Pain at tumor site due to obvious progression of disease  
 
Infusion reactions to Ofatumumab or Bendamustine which last less than 48 hours . 
 
Protocol Version 6.3 46 Hypersensitivity reactions (Grade ≤ 3 only) without use of proph ylactic pre -medications  
 
Adverse Event and Serious Adverse Event Reporting Period  
All Adverse Events (AEs) regardless of relationship to the study drug regimen will be collected  
from the initiation of any study procedures until 60 days following the last administration of 
study treatment. AEs are no longer required to be reported if a subject begins treatment with 
another therapy , including transplant.   
 
Once an investigator determines that an event meets the protocol definition of an SAE, the SAE 
will be reported to NOVARTIS  within 24 hours of being notified of the event  
 
All Serious Adverse Events ( SAEs) regardless of relationship to the study drug regimen  will be 
collected from the initiation of any study procedures  until the end of the follow -up period.   SAEs 
are no longer required to be reported if a subject begins treatment with another therapy , including 
transplant . SAEs related to underlying disease or progression of disease do not need to be 
reported to NOVARTIS . 
 
Preexisting Condition  
A preexisting  condition is one that is present at the start of the study. A preexisting condition will 
be recorded as an adverse event if the frequency, intensity, or the character of the condition 
worsens during the study period.  
 
General Physical Examination Findings  
At screening, any clinically significant abnormality will be recorded as a preexisting condition.  
At the end of the study, any new clinically significant findings/abnormalities that meet the 
definition of an adverse event will also be recorded and docume nted as an adverse event.   
 
Post-study Adverse Event  
All unresolved adverse events will be followed by the investigator until the events are resolved, 
the subject is lost to follow -up, or the adverse event is otherwise explained. At the last scheduled 
visit, the investigator will instruct each subject to report any subsequent event(s) that the subject, 
or the subject’s personal physician, believes might reasonably be related to participation in this 
study.    
  
Abnormal Laboratory Values  
A clinical laborato ry abnormality will be documented as an adverse event if any one of the 
following  conditions is met:   
 The laboratory abnormality is not otherwise refuted by a repeat test to confirm the 
abnormality  
 The abnormality suggests a disease and/or organ toxicity  
 The abnormality is of a degree that requires active management; e.g. change of dose, 
discontinuation of the drug, more frequent follow -up assessments, further diagnostic 
investigation, etc.  
 
Hospitalization, Prolonged Hospitalization or Surgery  
Any adverse event that results in hospitalization or prolonged hospitalization will be documented 
 
Protocol Version 6.3 47 and reported as a serious adverse event unless specifically instructed otherwise in this protocol. 
Slow infusion rate of ofatumumab (due to infusion reaction) needing ove rnight hospitalization to 
complete the infusion will not be recorded  as a serious adverse reaction. Any condition 
responsible for surgery will be documented as an adverse event if the condition meets the criteria 
for and adverse event.   
 
Neither the condit ion, hospitalization, prolonged hospitalization, nor surgery will be reported as 
an adverse event in the following circumstances:  
 Hospitalization or prolonged hospitalization for diagnostic or elective surgical procedures 
for a preexisting condition. Surge ry will not be reported as an outcome of an adverse 
event if the purpose of the surgery was elective or diagnostic and the outcome was 
uneventful.  
 Hospitalization or prolonged hospitalization required to allow efficacy measurement for 
the study.  
 Hospitaliz ation or prolonged hospitalization for therapy of the target disease of the study, 
unless it is a worsening or increase in frequency of hospital admissions as judged by the 
clinical investigator.  
 
8.2 Recording of Adverse Events  
At each contact with the su bject, the investigator will seek information on adverse events by 
specific questioning and, as appropriate, by examination. Information on all adverse events will 
be recorded immediately in the source document, and also in the appropriate adverse event 
module of the case report form (CRF). All clearly related signs, symptoms, and abnormal 
diagnostic procedures results will be recorded in the source document, though will be grouped 
under one diagnosis.  
 
All adverse events occurring during the study period m ust be recorded.  
 
The clinical course of each event will be followed until resolution, stabilization, or until it has 
been determined that the study treatment or participation is not the cause. Serious adverse events 
that are still ongoing at the end of t he study period must be followed up to determine the final 
outcome. Any serious adverse event (SAE) brought to the investigator’s attention after the 
subject has completed the study and is considered  by the investigator as  possibly related to the 
study treatment or study participation will be recorded and reported immediately.  
 
The investigator  must determine if an AE /SAE is in some way related to the study drug regimen. 
The relationship should be described as: Unrelated, Unlikely, Possibly, Probably or Def initely 
Related. 
 
8.3 Stopping Rules  
Accrual to the  Phase II trial will be stopped if the actual ORR rate is 25% or less. We will 
evaluate the ORR after 9 subjects have been treated and the trial will be terminated if 2 or fewer  
respond. Please see sectio n 7.2 for more information.  
 
8.4 Liver Chemistry Interruption/Stopping Criteria  
The sponsor -investigator is to review all events which meet liver chemistry stopping criteria to 
 
Protocol Version 6.3 48 determine if the event was due to ; 
 tumor lysis, disease related liver involveme nt 
 concomitant chemotherapy  
 other identified cause and to exclude drug induced liver injury (DILI) due to 
Ofatumumab  
 
If the event is determined to be due to causes other than Ofatumumab DILI and improvement is 
observed after withdrawal of Ofatumumab, rec hallenge may be attempted if deemed appropriate 
by the sponsor -investigator and in addition  to consent of the subject .  
 
Liver Chemistry Interruption/Stopping Criteria:  
1. ALT >3 times upper limit of normal (ULN) and bilirubin >2 times ULN (>35% direct 
bilirubin; bilirubin fractionation required)  
2. ALT >8 times ULN  
3. ALT >5 times ULN for more than 2 weeks  
 
When any of the liver chemistry stopping criteria is met, following will be done:  
 Immediately stop study treatment  
 Hold Ofatumumab for two weeks, repeat liver chemistry testing at least twice weekly, 
and report to sponsor-investigator to discuss the possibility of re -challenging with 
Ofatumumab . 
 Report SAE  to NOVARTIS  within 24 hours 
 All events of ALT > 3xULN and bilirubin > 2xULN (>35% direct bilirubin) (or 
ALT>3xULN and INR>1.5, if INR measured; INR measurement is not required and the 
threshold value stated will not apply to subjects receiving anticoagulants), termed ‘Hy’s 
Law’, must be reported as an SAE  (excluding studies of hepatic impairment or 
cirrhosis) . 
 
Liver chemistry follow -up assessments are to be followed until liver chemistries resolve, 
stabilize or return to baseline values . 
 
Liver Chemistry Follow -up Assessments  
The chemistry tests/ assessments below are to be performed at the time of the event an d then 
continued and/or discontinued at the discretion/judgment of the sponsor -investigator . 
 Viral hepatitis serology including:  
o Hepatitis A IgM antibody;  
o Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM);  
o Hepatitis C RNA;  
o Cytomegalovirus I gM antibody;   
o Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, obtain 
heterophile antibody or monospot testing);   
o Hepatitis E IgM antibody  
 Serum creatine phosphokinase (CPK) and lactate dehydrogenase (LDH)  
 Fractionate bilirubin, if tot al bilirubin >2xULN  
 Obtain complete blood count with differential to assess eosinophilia  
 
Protocol Version 6.3 49  Record the  appearance or worsening clinical symptoms of hepatitis, or hypersensitivity, 
fatigue, decreased appetite, nausea, vomiting, abdominal pain, jaundice, fever , or rash  
 Record use of concomitant medications, acetaminophen, herbal remedies, other over the 
counter medications, or putative hepatotoxins  
 Increased  alcohol use  
 
The following assessments are required for subjects with ALT >3xULN and bilirubin >2xULN  
(35% direct) but are optional for other abnormal liver chemistries:  
 Anti-nuclear antibody, anti -smooth muscle antibody, and Type 1 anti -liver kidney 
microsomal antibodies  
 Liver imaging (ultrasound, magnetic resonance, or computerized tomography) to evalu ate 
liver disease.  
 
Stopping Criteria:  
 For subject meeting liver stopping criteria 1:  
o A repeat of  liver chemistries within 24 hours, liver event follow -up assessments 
and close monitoring  
o A specialist or hepatology consultation is recommended  
o Monitor su bjects twice weekly until liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within baseline values.  
 For subjects meeting criteria 2 or 3:  
o A repeat of  liver chemistries within 24 to 72 hours for repeat liver che mistries 
and liver event follow -up assessments  
o Monitor subjects weekly until liver chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) resolve, stabilize or r eturn to within baseline values  
 After holding Ofatumumab for two weeks:  
o If the treatment is exhibiting efficacy and the subject wants to continue therapy 
after being informed of the results of liver chemistry testing, then the 
Ofatumumab may be re -started.  
o Liver chemistries and follow -up assessments should be monitored at a minimum 
of every 2 we eks until resolution, stabilization, or a return to baseline values, at 
which point monitoring should be continued per protocol  
 Subjects with ALT >3xULN but <5xULN and bilirubin <2xULN without hepatitis 
symptoms or rash, and who may be monitored weekly for  at least 4 weeks, then the 
following actions should be taken:  
o Subjects can continue Ofatumumab  
o Weekly repeat of liver chemistries until they resolve, stabilize, or return to 
baseline values, then monitor liver chemistries as per protocol assessment 
schedule 
 
If at any time the subject meets any of the liver chemistry stopping criteria, then proceed as 
described above . 
 
If after 4 weeks of monitoring, ALT<3xULN and bilirubin<2xULN monitor twice monthly until 
liver chemistries normalize or return to within b aseline values . 
 
 
Protocol Version 6.3 50 8.5 Data and Safety Monitoring Plan  
It is the responsibility of the Principal Investigator to oversee the safety of the study. This safety 
monitoring will include careful assessment and appropriate reporting of adverse events as noted 
above, as well as the compliance and implementation of the KCC data and safety -monitoring 
plan. Medical monitoring will include a regular assessment of the number and type of serious 
adverse events by both the assigned Medical Monitor and the KCC DSMC.  
 
 
8.5.1 Medical Monitoring and AE/SAE Reporting  
 
The principal investigator has the obligation to report all serious adverse events to the FDA, IRB, 
and Novartis Pharmaceuticals Drug Safety and Epidemiology Department (DS&E).  
All events reported to the FDA by the  investigator are to be filed utilizing the Form FDA 3500A 
(MedWatch Form).  
To ensure patient safety, every SAE, regardless of suspected causality, occurring  
 after the patient has provided informed consent and until at least 30 days  after the patient has 
stopped study treatment/participation  
 after protocol -specified procedures begin (e.g., placebo run -in, washout period, double -blind 
treatment, etc.) and 30 days after the patient has stopped study treatment  
 after the start of any period in which the study protocol interferes with the standard medical 
treatment given to a patient (e.g., treatment withdrawal during washout period, change in 
treatment to a fixed dose of concomitant medication) and until 30 days after the patient has 
stopped study treatment  
 must be reported to Novartis U.S. Drug Safety and Epidemiology within 24 hour s of learning of 
its occurrence.  
Report to Novartis via Fax:  
  U.S. Drug Safety & Epidemiology   at  Fax #: 877 -778-9739 
 Should the designated SAE Fax# be non -functional please send SAEs to the designated 
SAE mailbox: clinicalsafetyop.phuseh@novartis.com  
 Attach Novartis Coversheet to all SAE submissions  
 Reference Novartis Study Number COMB157DUS09T  
This includes serious, related, not related, labeled (expected) and, unlabeled (unexpected) 
adverse exper iences. All deaths during treatment or within 30 days following completion of 
active protocol therapy must be reported within24 hours.  
Any SAEs experienced after this 30 days period should only be reported to Novartis if the 
investigator suspects a causal relationship to the study drug. Recurrent episodes, complications, 
or progression of the initial SAE must be reported as follow -up to the original episode within 24 
hours of the investigator receiving the follow -up information. A SAE occurring at a differe nt 
time interval or otherwise considered completely unrelated to a previously reported one should 
be reported separately as a new event.  The end date of the first event must be provided.  
The original copy of the SAE Report and the fax confirmation sheet m ust be kept within the 
Trial Master File at the study site.  
 
Protocol Version 6.3 51 Follow-up information is sent to the same fax number as the original SAE Report Form was sent, 
using a new fax cover sheet, stating that this is a follow -up to the previously reported SAE, and 
giving the date of the original report. Each re -occurrence, complication, or progression of the 
original event should be reported as a follow -up to that event regardless of when it occurs. The 
follow-up information should describe whether the event has resolv ed or continues, if and how it 
was treated, whether the blind was broken or not (if applicable), and whether the patient 
continued or withdrew from study participation.  
If the SAE is not previously documented in the Ofatumumab Investigator Brochure or Pack age 
Insert (new occurrence) and is thought to be related to the Novartis study drug, a DS&E 
associate may urgently require further information from the investigator for Health Authority 
reporting. Novartis may need to issue an Investigator Notification (IN ), to inform all 
investigators involved in any study with the same drug that this SAE has been reported.  
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in a ccordance with Directive 
2001/20/EC or as per national regulatory requirements in participating countries.  
 
 
For medical emergencies, the contact is:  
 
Gaetano Bonifacio MD  
Medical Director  
US CD MA Hematology  
Novartis Pharmaceuticals Corporation                                    
One Health Plaza, 345/4th  
East Hanover, NJ 07936 -1080 
Mobile  +1 610 427 3613  
gaetano.bonifacio@novartis.com  
 
 
 
A Medical Monitor is assigned to this study at the Thomas Jeffers on University. This is a 
physician/pharmacist who is not directly involved in the trial, and is not currently collaborating with 
the sponsor/investigator on any other trial. The role of the Medical Monitor is to review all 
reportable AEs/SAEs (in real -time) including grading, toxicity assignments, non -reportable AEs 
(quarterly), protocol violations/deviations, as well as all other safety data and activity data observed 
in the ongoing clinical trial occurring at Thomas Jefferson University. The Medical Monit or may 
recommend reporting of adverse events and relevant safety data, and may also recommend 
suspension or termination of the study to the DSMC and TJU IRB.   
 
Every KCC investigator initiated protocol includes requirements for reporting of adverse events  
based on CTC 4.0. All events are reported to the IRB and Medical Monitor using a password 
protected web -site. In addition all serious adverse events (SAEs) are reported to the TJU IRB  
 Investigator/Study Sponsor will be responsible for reporting SAEs to the Food and Drug 
Administration (FDA) if applicable. The investigator is required to submit all serious adverse 
events to the TJU IRB and the Medical Monitor within the timeframes outlined in the below 
table. All AE/SAEs will be reported to the DSMC at th e quarterly DSMC review meetings; 
however, if the Medical Monitor determines corrective action is necessary, an “ad hoc” DSMC 
 
Protocol Version 6.3 52 meeting will be called. Fatal adverse events related to treatment which are unexpected must be 
reported within 24 hours to the TJU  IRB and the DSMC. Fatalities not related to the study 
drug/device must be reported within 5 days . A summary of the reporting procedure is  presented 
below.  
 
 Grade 1  Grade 2  Grade 2  Grade 3  Grade 3  Grades 4 
and 5  
 Unexpected 
and 
Expected  Unexpected  Expec ted Unexpected 
with 
Hospitalization  Unexpected 
without 
Hospitalization  Expected with 
Hospitalization  Expected 
without 
Hospitalization  Unexpected 
and 
Expected  
Unrelated  
Unlikely  Reviewed 
at Quarterly 
DSMC 
Meeting 
and IRB 
Annual 
Review  Reviewed 
at Quarterly  
DSMC 
Meeting 
and IRB 
Annual 
Review  Reviewed 
at 
Quarterly 
DSMC 
Meeting 
and IRB 
Annual 
Review  5 Working 
Days  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  5 Working 
Days  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  Phase 1 -             
48 Hours   
(Death: 24 
Hours)  
 
Phase 2 -            
5 Working 
Days          
Possible  
Probable  
Definite  Reviewed 
at Quarterly 
DSMC 
Meeting 
and IRB 
Annual 
Review  5 working 
days  Reviewed 
at 
Quarterly 
DSMC 
Meeting 
and IRB 
Annual 
Review  48 Hours    
(Death: 2 4 
Hours)  Phase 1 -             
48 Hours   
 
Phase 2 -              
5 Working 
Days  48 Hours    
(Death: 24 
Hours)  Reviewed at 
Quarterly 
DSMC 
Meeting and 
IRB Annual 
Review  Phase 1 
and Phase 
2 -             
48 Hours         
(Death: 24 
Hours)  
 
 
**NOTE: This tab le is based on the NCI AE/SAE reporting Guidelines and the TJU IRB Policy and Procedures. 
Please follow the individual protocol AE/SAE reporting guidelines if more stringent reporting procedures are 
specified.  
***See section 8.1 for exceptions to this moni toring plan.  
 
8.5.2 Data and Safety Monitoring Committee  
Data and Safety Monitoring Committee (DSMC) is the Data and Safety Monitoring Board 
(DSMB) for the KCC. The DSMC is a multidisciplinary committee charged with overseeing the 
monitoring of safety of p articipants in clinical trials, and the conduct, progress, validity, and 
integrity of the data for all clinical trials at the Thomas Jefferson University KCC. The committee 
meets quarterly to review the progress and safety of all active research protocols that are not 
monitored by another safety and data monitoring committee or board.  
 The DSMC meets quarterly. Additional DSMC meetings are scheduled based on the 
nature and number of trials being monitored over a specified time period. The DSMC 
 
Protocol Version 6.3 53 meets (by conf erence call) within 24 hours following the notification of an unexpected 
adverse event felt to be related to the study drug.  
 Prior to each DSMC meeting, each board member, is provided a printout of all reported 
AEs and SAEs occurring during the reporting period for this clinical trial. The principal 
investigator provides a detailed and comprehensive narrative assessment of current 
adverse events to date, indicating their possible significance and whether these toxicities 
have affected the conduct of the tr ial. DSMC members are provided with the principal 
investigator’s assessment, a written report summarizing adverse events, safety data, and 
activity data observed during the specified time period described in each protocol, as well 
as recommendations from t he Medical Monitor. A review of outcome results (response, 
toxicity and adverse events) and factors external to the study (such as scientific or 
therapeutic developments) is discussed, and the Committee votes on the status of each 
study.  
 A summary of the board’s action is sent to each investigator, the CCRRC and TJU IRBs. 
The DSMC actions may include recommendations/requirements that will lead to 
improved patient safety and/or efficacy, significant benefits or risks that have developed, 
or other changes de termined to be necessary. The DSMC may also take note of slow 
accrual or lack of scientific progress, and refer such issues to the CCRRC. The DSMC 
provides the investigator with the rationale for any decision made.  
 
9.0 Data handling and Record Keeping  
9.1 Confidentiality  
Information about study subjects will be kept confidential and managed according to the 
requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  
Those regulations require a signed subject authorization inf orming the subject of the following:  
 What protected health information (PHI) will be collected from subjects in this study  
 Who will have access to that information and why  
 Who will use or disclose that information  
 The rights of a research subject to revok e their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
regulation, retains the ability to use all information collected prior to the revocation of subject 
authorization. F or subjects that have revoked authorization to collect or use PHI, attempts will be 
made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of 
their scheduled study period.  
 
9.2 Source Documents  
Source data is  all information, original records of clinical findings, observations, or other 
activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source 
data are contained in source documents   Examples of these original documen ts, and data records 
include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies or transcriptions certified a fter verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories, and at medico -technical departments involved 
in the clinical t rial. 
 
Protocol Version 6.3 54  
9.3 Case Report Forms  
The study case report form (CRF) is the primary data collection instrument for the study.  All 
data requested on the CRF must be recorded.  All missing data must be explained.  If a space on 
the CRF is left blank because the pr ocedure was not done or the question was not asked, write 
“N/D”.  If the item is not applicable to the individual case, write “N/A”.  All entries will be 
printed legibly in black ink.  If any entry error has been made, to correct such an error, draw a 
single straight line through the incorrect entry and enter the correct data above it.  All such 
changes must be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For 
clarification of illegible or uncertain entries, print the clarification above the item , then initial and 
date it.  
 
9.4 Records Retention  
It is the investigator’s responsibility to retain study essential documents for at least 2 years after 
the completion and termination of the protocol.  
 
10.0 Study Monitoring, Auditing and Inspecting  
10.1 Study Monitoring Plan  
The investigator will allocate adequate time for monitoring activities. The Investigator will also 
ensure that the medical monitor or other compliance or quality assurance reviewer is given 
access to all the above noted study -related documents and study related facilities (e.g. pharmacy, 
diagnostic laboratory, etc.), and has adequate space to conduct the monitoring visit.  
 
KCC Investigator Initiated Phase I Studies  
Phase I studies require continuous monitoring by the PI of the study with quarterly safety and 
monitoring reports submitted to the CRMO and the DSMC. Each protocol is assigned to a 
medical monitor (a physician or other member of the DSMC who has expertise in the therapeutic 
area of the protocol and is not directly involved in this trial). The medical monitor reviews all 
adverse events (in addition to unexpected adverse events), safety data and activity data observed 
in the ongoing clinical trial at each new dose level, prior to dose escalation.  
 
The PI provides a report to the DSMC of all AE/SAEs, safety and toxicity data, and any 
corrective action that occurred on a quarterly basis. The medical monitor also provides a 
summary of their review. The summary of all discussions of adverse events are submitted to the 
DSMC, and th ese reports are reviewed during the DSMC meetings that take place quarterly. 
Patients are only identified by initials, and no other personal health information (PHI) is included 
in the reports.  
 
The medical monitor may recommend reporting adverse events a nd relevant safety data not 
previously reported, and may recommend suspension or termination of the trial based on their 
review of AE/SAE data observed throughout the life of a clinical trial. In such circumstances, 
and “ad hoc” DSMC meeting will be called  to discuss corrective action with the PI. If for any 
reason the PI of the trial disagrees with the conclusions of the Medical Monitor or DSMC, the 
issue will be referred to the Associate Director of Clinical Investigations, who will be 
responsible for dis pute resolution.  
 
 
Protocol Version 6.3 55 The summary of all discussions of adverse events are included in the KCC investigator’s reports 
to the TJU IRBs as part of its annual progress report. The DSMC and the TJU IRBs may, based 
on the monitor’s recommendation suspend or termin ate the trial. The quarterly safety and 
monitoring reports include a statement as to whether this data has invoked any stopping criteria 
in the clinical protocol.  
 
KCC Investigator Initiated Phase II Studies  
Phase II studies require monthly monitoring by  the PI of the study with quarterly safety and 
monitoring reports submitted to the CRMO, and the DSMC. Each protocol is assigned to a 
medical monitor (a physician or other member of the DSMC who has expertise in the therapeutic 
area of the protocol and is not directly involved in this trial). The medical monitor reviews all 
adverse events (in addition to unexpected adverse events), safety data and activity data observed 
in the ongoing clinical trial.  
 
The PI provides a report to the DSMC of all AE/SAEs, sa fety and toxicity data, and any 
corrective action that occurred on a quarterly basis. The medical monitor also provides a 
summary of their review. The summary of all discussions of adverse events are submitted to the 
DSMC, and these reports are reviewed du ring the DSMC meetings that take place quarterly. 
Patients are only identified by initials, and no other PHI is included in the reports.  
 
The medical monitor may recommend reporting adverse events and relevant safety data not 
previously reported, and may recommend suspension or termination of the trial based on their 
review of AE/SAE data observed throughout the life of a clinical trial. In such circumstances, 
and “ad hoc” DSMC meeting will be called to discuss corrective action with the PI.  
 
The summary of all discussions of adverse events are included in the KCC investigator’s reports 
to the TJU IRBs as part of its annual progress report. The DSMC and the TJU IRB may, based 
on the monitor’s recommendation suspend or terminate the trial. The quarterly saf ety and 
monitoring reports include a statement as to whether this data has invoked any stopping criteria 
in the clinical protocol.  
10.2 Auditing and Inspecting  
The investigator will permit study -related monitoring, audits, and inspections by the IRB, the 
funding sponsor, government regulatory bodies, and University compliance and quality 
assurance groups of all study related documents (e.g. source documents, regulatory documents, 
data collection instruments, study data etc.).  The investigator will ensure the capability for 
inspections of applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
 
Participation as an investigator in this study implies acceptance of potential inspection by 
government regulatory authorities and applicab le University compliance and quality assurance 
offices. 
 
10.2.1 Independent External and Internal Audits  
In addition to review by the DSMC, all studies initiated by KCC investigators are audited by an 
independent auditor once they have achieved 10% of tar get accrual. However, a study can be 
audited at any time based on recommendations by the IRB, DSMC, CCRRC and/or the Director 
 
Protocol Version 6.3 56 of Clinical Investigations, KCC. Studies are re -audited once they have achieved 50% of target 
accrual. Special audits may be recom mended by the IRB, DSMC or CCRRC based on prior 
findings, allegations of scientific misconduct and where significant irregularities are found 
through quality control procedures. Any irregularities identified as part of this process would 
result in a full a udit of that study.  
 
In addition to the audits at 10 and 50%, the CRMO randomly audits at least 10 percent of all 
patients entered into therapeutic KCC trials and other trials as necessary, on at least a bi -annual 
basis, to verify that there is a signed a nd dated patient consent form, the patient has met the 
eligibility criteria, and that SAEs are documented and reported to the TJU IRB.  
 
All audit reports are submitted to the DSMC for review and action (when appropriate). A copy of 
this report and recomme nded DSMC action is sent to the CCRRC and TJU IRB. The committee 
regards the scientific review process as dynamic and constructive rather than punitive. The 
review process is designed to assist Principal Investigators in ensuring the safety of study 
subjects and the adequacy and accuracy of any data generated. The TJU IRB may, based on the 
DSMC and auditor’s recommendation, suspend or terminate the trial.  
 
11.0 Ethical Considerations  
This study is to be conducted according to US and international standards  of Good Clinical 
Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), 
applicable government regulations and Institutional research policies and procedures.  
 
This protocol and any amendments will be submitted to a prop erly constituted independent 
Institutional Review Board (IRB), in agreement with local legal prescriptions, for formal 
approval of the study conduct. The decision of the IRB concerning the conduct of the study will 
be made in writing to the investigator be fore commencement of this study.   
 
All subjects for this study will be provided a consent form that is compliant with local and 
federal regulations, describing this study and providing sufficient information for subjects to 
make an informed decision about  their participation in this study. This consent form will be 
submitted with the protocol for review and approval by the IRB for the study.  The formal 
consent of a subject, using the IRB -approved consent form, must be obtained before that subject 
is submitted to any study procedure. This consent form must be signed by the subject or legally 
acceptable surrogate, and the investigator -designated research professional obtaining the consent.  
 
12.0 Study Finances  
12.1 Funding Source  
The study  was supported by  GSKand remaining support to be provided by  Novartis  
 
12.2 Conflict of Interest  
None to report  
 
13. Publication Plan  
We intend to publish our results in a peer reviewed journal and to present our data at a reputable 
National or International meeting. The primary responsibility for publication lies with the PI and 
 
Protocol Version 6.3 57 statistician.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES  
1. Levitt M, Marsh JC, DeConti RC, et al. Combination sequential chemotherapy in advanced reticulum cell 
sarcoma.Cancer. 1972;  29:630-636. 
2. DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic 
lymphoma, a potentially curable disease.Lancet. 1975;  1:248-250. 
3. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive 
chemotherapy regimens for advanced non -Hodgkin’s lymphoma. N Engl J Med. 1993;  328:1002 -1006. 
4. Pfreundschuh M, Tru¨mper L, Osterborg A, et al: CHOP -like chemotherapy plus rituximab versus CHOP -
like chemotherapy alone in young patients with good -prognosis diffus e large-B-cell lymphoma: A 
randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379 -391, 
2006 
5. Bertrand Coiffier et al. Long -term outcome of patients in the LNH -98.5 trial, the first randomized study 
comparing rituxim ab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the 
Grouped'Etudes des Lymphomes de l'Adulte Blood 2010 116: 2040 -2045. 
6. Hamlin PA, Zelenetz AD, Kewalramani T, et al: Age -adjusted International Prognostic Index predicts 
autologous stem c ell transplantation outcome for patients with relapsed or primary refractory diffuse large 
B-cell lymphoma. Blood 102:1989 -1996, 2003  
7. Kewalramani T. Rituximab and ICE as second -line therapy before autologous stem cell transplantation for 
relapsed or primar y refractory diffuse large B -cell lymphoma. Blood 2004 May 15;103(10):3684 -8. 
8. Christian Gisselbrecht, et al Salvage Regimens With Autologous Transplantation for Relapsed Large B -
Cell Lymphoma in the Rituximab Era  JCO Sep 20, 2010:4184 -4190 
9. Velasquez WS , Cabanillas F , Salvador P , McLaughlin P , Fridrik M , Tucker S, Jagannath S , Hagemeister 
FB,Redman JR , Swan F, et al. Effective salvage therapy for lymphom a with cisplatin in combination with 
high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 Jan;  71(1):117 -22. 
10. Alejandro Martín et al. R-ESHAP as salvage therapy for patients with re lapsed or refractory diffuse large 
B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO 
study.Haematologica,2008 Vol 93, Issue 12, 1829 -1836 
11. Jermann M et al. Rituximab -EPOCH an effective salvage therapy for  relapsed, refract ory or transformed B -
cell lymphomas: results of a phase II study. Ann Oncol. 2004 Mar;  15(3):511 -6. 
 
Protocol Version 6.3 58 12. Lopez A et al. GEMOX -R regimen is a highly effective  salvage regimen in patients with 
refractory/relapsing diffuse large -cell lymphoma : a phase II study. 20 08 Feb; 80(2):127 -32.  
13. Teeling JL, French RR, Cragg MS, et al. Characterizationof new human CD20 monoclonal antibodies  with 
potent cytolytic activity against non -Hodgkin lymphomas. Blood. 2004;104:1793 -1800. 
14. Teeling JL, Mackus WJ, Wiegman LJ, et al. The bi ological activity of human CD20 monoclonal antibodies 
is linked to unique epitopes on CD20.J Immunol. 2006;177:362 -371. 
15. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, 
Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. Safety and efficacy of 
ofatumumab, a fully human monoclonal anti -CD20 antibody, in patients with relapsed or refractory B -cell 
chronic lymphocytic leukemia: a phase 1 -2 study. Blood. 2008 Feb 1;111(3):1094 -100.  
16. Hagenbeek A et al. First clinical use of ofatumumab, a novel fully human anti -CD20 monoclonal antibody 
in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008 Jun 15;111  
(12):5486 -95. 
17. M S Czuzman Ofatumumab combined with CHOP in pr eviously untreated patients with follicular 
lymphoma (FL). Abstract 8042, 2010 ASCO  Annual Meeting  
18. W G Wierda et al Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O -FC) in 
previously untreated patients with chronic lymphocytic leuk emia (CLL). Abstract 6520,  2010 ASCO  
Annual Meeting  
19. Wierda, et al.Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O -FC) in 
previously untreated patients with chronic lymphocytic leukemia Blood 2011 blood -2010-12-323980 
20. Leoni LM. Be ndamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic 
features compared with other alkylating agents. Clin Cancer Res 2008 Jan 1;14(1):309 -17. 
21. Friedberg JW , Cohen P, Chen L, Robinson KS , Forero-Torres A, La Casce AS , Fayad LE , Bessudo A, 
Camacho ES , Williams ME , van der Jagt RH , Oliver JW , Cheson BD . Bendamustine in patients with 
rituximab -refractory indolent and transformed non -Hodgkin's lymphoma: results from a phase II 
multicenter, single -agent study.  J ClinOncol. 2008 Jan 10;26(2):204 -10 
22. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce 
R, van der Jagt RH, Cheson BD. Bendamustine is effective therapy in patients with rituximab -refractory, 
indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010 Jan 1;116(1):106 -
14. 
23. Chow KU, Sommerlad WD, Boehrer S, et al: Anti -CD20 antibody (IDEC -C2B8, rituximab) enhances 
fficacy of cytotoxic drugs on neoplastic ymphocytes in vitro: Rol e of cytokines, complement, and caspases. 
Haematologica 87:33 -43, 2002 
24. Robinson KS. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent 
B-cell and mantle cell non -Hodgkin's lymphoma. J ClinOncol. 2008 Sep 20;  26(27):4473-9. 
25. Weide R. High anti -lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated 
relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the 
German Low Grade Lymphoma Study Group (GLS G). Leuk Lymphoma 2007 Jul;  48(7):1299 -306. 
26. J LVacirca. Bendamustine/rituximab in relapsed or refractory diffuse large B -cell lymphoma.  Abstract 
8041,  2010 ASCO  Annual Meeting  
27. Jilani, I., S. O’Brien, T. Manshuri, D. A. Thomas, V. A. Thomazy, M. Imam, S.  Naeem, S. Verstovsek, H. 
Kantarjian, F. Giles, et al. 2003. Transient down modulation of CD20 by rituximab in patients with chronic 
lymphocytic leukemia. Blood 102: 3514 –3520. 
28. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Mu ller-Hermelink 
HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, 
Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, 
Lynch JC, Vose J, Armitage JO, Montserrat E, López -Guillermo A, Grogan TM, Miller TP, LeBlanc M, 
Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular 
Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large -B-
cell lymphoma. N Engl J Med. 2002;  346(25):1937.  
29. Confirmation of the molecular classification of diffuse large B -cell lymphoma by immunohistochemistry 
using a tissue microarray. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, 
Müller-Hermelink  HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham 
AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Blood. 2004;103(1):275.  
 
Protocol Version 6.3 59 30. Gibson SE, Hsi ED.Epstein-Barr virus -positive B -cell lymphoma of the elderly at a United States tertiary 
medical center: an uncommon aggressive lymphoma with a nongerminal ce nter B-cell phenotype. Hum 
Pathol. 2009 May;  40(5):653 -61.  
31. Aukema SM , Siebert R , Schuuring E , van Imhoff GW , Kluin-Nelemans HC , Boerma EJ , Kluin PM . 
Double-hit B-cell lymphomas. Blood 2011 Feb 24;117(8):2319 -31. Epub 2010 Nov 30.  
32. Yu L, Slovak ML , Mannoor K , Chen C, Hunger SP , Carroll AJ , Schultz RA , Shaffer LG , Ballif BC , Ning 
Y. Microarray detection of multiple recurring submicroscopic chromosomal aberrations in pediatric T -cell 
acute lymphoblastic leukemia. Leukemia advan ce online publication, 8 March 2011  
33. Cheson BD , Pfistner B , Juweid ME , Gascoyne RD , Specht L, Horning SJ , Coiffier B , Fisher RI, 
Hagenbeek A , Zucca E, Rosen ST , Stroobants S , Lister TA , Hoppe RT , Dreyling M , Tobinai K , Vose JM, 
Connors JM , Federico M , Diehl V; International Harmonization Project on Lymphoma . Revised response 
criteria for malignant lymphoma. J Clin Oncol.  2007 Feb 10;  25(5):579 -86. 
34. Hallek M et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from 
the Internation al Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute –
Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446 -56 
 
 
 
 
 
 
 
 
APPENDI CES 
 
Appendix 1 : Second Line Age Adjusted International Prognostic Index (sAAIPI)  
 
Risk factors:  Score 
LDH >ULN  1 
Stage III or IV  1 
KPS <80%  1 
 
Low risk (L) with 0 factors, low intermediate (LI) risk with 1 factor, high -intermediate risk (HI) 
with 2 factors, and high r isk (H) with all 3 factors present.  
 
 
Protocol Version 6.3 60  
Appendix 2: ECOG Performance Status  
 
Grade  ECOG 
0  Fully active, able to carry on all pre disease performance without 
restriction  
1  Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work  
2  Ambulatory and capable of all self -care but unable to carry out any work 
activities. Up and about more than 50% of waking hours  
3   Capable of only limited self -care, confined to  bed or chair more than 
50% of waking hours   
4 Completely disabled. Cannot carry on any self -care. Totally confined to 
bed or chair  
5 Dead 
 
Ref: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And  
Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649 -655, 1982.  
 
 
Protocol Version 6.3 61  
 
Appendix 3: Tissue Freezing and Storage Procedure  
 
After adequate tissue has been utilized for the diagnostic and correlative studies, the remained of 
the fresh tissue (lymph node tissue, bone marrow or other tissue obtained for diagnostic purposes 
and correlative studies) will be frozen and stored to be utilized for additional correlative tests as 
per protocol (section 6.5) or for future IRB approved studies.  Subjects will be asked to sign a 
consent form if they allow their tissue to be stored for  additional tests as per current correlative  
protocol and also if they allow it to be used for future  research purposes. If they refuse, the 
remained of the collected  tissue will not be stored to be utilized for current or for any future 
studies. 
 
Tissue Freezing Procedure  
1. The tissue, approximately 3-5mm thickness  or more will be placed into a plastic container 
labeled with the specimen number, person ID number and  source of tissue.  
2. The container will be wrapped in foil and a specimen number sticker is placed on the outside 
of the foil. The container with the foil is then put into the liquid nitrogen flask  to be snap frozen. .  
3. The sample will then be transfer red to the –70°C freezer and stored  until used for research. . 
4. A log of the sample stored will be maintained in the tissue bank and in the CRMO. The 
following information will be recorded in the log:   
 Specimen ID  
 Name  
 Date of Birth  
 Tissue type  
 Consent form  
 Date Tissue Taken  
 Time to freeze/fix tissue  
 Date blocks processed  
 Number of tumor pieces frozen  
 Additional specimens taken  
 Storage of additional specimens  
 Relevant a dditional information/comments  
 
 
 
 
Protocol Version 6.3 62 Appendix 4: Study Procedures Schedule  
Procedures  Screen ing1 Treatment10 
 Follow -up Procedures11 
  Cycle 1 Cycle 
2 Cycle 
3 Post 
treatment 
assessment12 Treatment 
withdrawal  or 
disease progression  3 months post treatment 
or post ASCT  6, 9, 12, 18 
and 24 months 
post treatment  
or post ASCT  
Informed  Consent  X        
Demography  X        
Medical History  X        
Disease History  X        
Therapy History  X        
  
Efficacy 
assessment   
 
Bone Marrow 
biopsy    
X2    
X14    
Lymph 
node/mass 
biopsy X3    X3 X3   
CT (or MRI) X4  X4  X4  X13 X13 
PET/CT X4  X4  X4  X13 X13 
Clinic al disease 
assessment  X X X X X X   
Disease 
assessment and 
survival        X X 
  
Safety 
Assessments    
Physical Exam  X X X X X    
ECOG 
performance5 X    X    
Height  X        
Weight  X X X X X    
Vital Signs  X X X X X    
12-lead ECG  X        
MUGA or ECHO  X6        
Toxicity 
Assessment   X X X X    
Concomitant 
Medications  X X X X     
         
         
         
Procedures  Screen ing1 Treatment10 
 Follow -up Procedures11 
  Cycle 1  Cycle 
2 Cycle 
3 Post 
treatment 
assessment12  Treatment 
withdrawal  or 
disease progression  3 months post treatment 
or post ASCT  6, 9, 12, 18 
and 24 months 
post treatment  
or post ASCT  
Lab  
 
Protocol Version 6.3 63 Assessments  
Hematology 
(CBC with 
differential)  X X X X  X   
Chemistry (CMP -
12), Uric acid, 
LDH, B2M  X X X X  X   
Serum Pregnancy 
Test X7 X7 X7 X7  X7   
Hepatitis B&C 
screen8 X        
HIV screen  X        
IgG, IgM, IgA  X    X X   
  
Dispense Study 
Medication   
Ofatumumab   X X X     
Bendamustine   X X X     
Carboplatin   X X X     
Etoposide   X X X     
  
Correlative 
studies9  
Flow cytometry 
for CD20  X        
IHC including  
CD20, Bcl -2, Bcl -
6, Cyclin D1  X        
FISH:  FISH for 
Bcl-2, Bcl -6 and 
MYC 
rearrangement  X        
EBER by in situ 
hybridization  X        
Cryopreservation 
and storage of 
malignant cel ls 
from diagnostic 
tumor biopsy  X        
1 To be done within 28 days  of initiation of C ycle 1, unless otherwise noted . Such 
screening studies as  
2 To be done if involved at the time of initial diagnosis or if clinically indicated  
3 It is strongly recommended ( but not mandatory ) that additional diagnostic tissue biopsies 
are performed, when possible, to confirm diagnosis, relapse or tumor progression  
4 Imaging studies  will be performed before therapy (within 4 weeks of initiation of 
treatment). If patient had a PE T/CT scan done within 6 weeks of starting treatment  all 
efforts should be made  to have a new study done within 4 weeks of starting  treatment , 
however, if rejected by the insurance company the patient will still be eligible for the trial 
and the PET/CT that  was done with 6 weeks will be counted as baseline study .CT or MRI 
should be done within 4 weeks of initiation of treatment . CT and MRI (if patient had a  
 
Protocol Version 6.3 64 positive MRI before treatment) will be repeated after 2 cycles and PET /CT scan will be 
performed after  3 cycles of therapy. Restaging PET /CT will be performed after Cycle 2 
(in addition to other restaging studies) if stem cell transplant is planned after 2 cycles or if 
tumor progression is suspected based on other restaging studies. CT or/and MRI may be 
repeated after 3 cycles in addition to PET /CT upon discretion of study PI or a treating 
physician. 
5 See Appendix 2 for ECOG performance status assessment  
6 MUGA or ECHO can be performed up to 3 months prior to start of treatment  
7 For women of childbearing age:  Serum pregnancy testing should be performed within 3 
days prior to enrol lment, prior to each cycle if last test was more than 30 days prior and at 
6 months after last cycle of the study regimen.  
8 Hepatitis B screen should include HepBcAb, HepBsAg, and HepBsAb. If HepBsAg is 
negative and HepBcAb is positive a quantitative PCR analysis for HepB DNA should be 
performed. (see study exclusion criteria)   
9 Strongly recommended but not mand atory 
10 Day 1 study procedures of each cycle can be done up to 72 hours prior to D ay 1. ) In the 
event of a pr olonged ofatumumab infusion (> 8 hours) it is acceptable to reschedule the 
rest of day 1 chemotherapy to the following day. In that case day 2 and day 3 
chemotherapy will be rescheduled to day 3 and 4, respectively.  
11 Follow up pr ocedures should be performed at Months 3, 6, 9, 12, 18 and 24 months post 
treatment or post ASCT with a window of ± 1 month  
12 Post treatment assessment should be completed between 3 -8 weeks post treatment  
13 Follow up PET/CT scans will be done  per institutional  guidelines post treatment or post 
transplant.  A diagnostic quality, contrast enhanced CT scan of the chest,  abdomen and 
pelvis (and neck, if done at baseline or if a new suspected area of involvement) or/and 
MRI of any site can be added at any restaging t ime point upon discretion of the study PI, 
a co-investigator or a treating physician. If at any time point starting from  month 3 post 
chemotherapy,  a problem occurs with precertificati on of a particular PET/CT scan 
(documentation is  required for each time  point), a diagnostic quality CT scan (as 
described above) or/and MRI (if done at baseline), are accepta ble for restaging purposes   
14 To be done if positive at screening  
 
Protocol Version 6.3 65  
Appendix 5  
 
Revised Response Criteria for Malignant Lymphoma.  
Cheson BD, Pfistner B, J uweid ME, et al.. J Clin Oncol 2007;25:579 –86 
 
CR 
1. Complete disappearance of all detectable clinical evidence of disease and disease -related 
symptoms if present before therapy.  
 
2a. Typically FDG -avid lymphoma: in patients with no pretreatment PET scan o r when the PET 
scan was positive before therapy, a post -treatment residual mass of any size is permitted as long 
as it is PET negative.  
 
2b. Variably FDG -avid lymphomas/FDG avidity unknown: in patients without a pretreatment 
PET scan, or if a pretreatment  PET scan was negative, all lymph nodes and nod al masses must 
have regressed on CT to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes > 
1.5 cm before therapy). Previously involved nodes that were 1.1 to 1.5 cm in their long axis and 
more than 1.0 cm in their short axis before trea tment must have decreased to ≤ 1.0 cm in their 
short axis after treatment.  
 
3. The spleen and/or liver, if considered enlarged before therapy on the basis of a physical 
examination or CT scan, should not be palpable on physical examination and should be 
considered normal size by imaging studies, and nodules related to lymphoma should disappear. 
However, determination of splenic involvement is not always reliable because a spleen 
considered normal in size may still contain lymphoma, whereas an enlarged sple en may reflect 
variations in anatomy, blood volume, the use of hematopoietic growth factors, or causes other 
than lymphoma.  
 
4. If the bone marrow was involved by lymphoma before treatment, the infiltrate must have 
cleared on repeat bone marrow biopsy. Th e biopsy sample on which this determination is made 
must be adequate (with a goal of > 20 mm unilateral core). If the sample is indeterminate by 
morphology, it should be negative by immunohistochemistry. A sample that is negative by 
immunohistochemistry bu t that demonstrates a small population of clonal lymphocytes by flow 
cytometry will be considered a CR until data become available demonstrating a clear difference 
in patient outcome.  
 
CRu 
The use of the above definition for CR and that below for PR elimi nates the category of CRu.  
 
PR 
The designation of PR requires all of the following:  
 
 
Protocol Version 6.3 66 1. At least a 50% decrease in sum of the product of the diameters (SPD) of up to six 
of the largest dominant nodes or nodal masses. These nodes or masses should be 
selected according to all of the following: they should be clearly measurable in at 
least 2 perpendicular dimensions; if possible they should be from disparate 
regions of the body; and they should include mediastinal and retroperitoneal areas 
of disease whenever th ese sites are involved.  
 
2. No increase should be observed in the size of other nodes, liver, or spleen.  
 
3. Splenic and hepatic nodules must regress by ≥ 50% in their SPD or, for single nodules, in 
the greatest transverse diameter.  
 
4. With the exception of splen ic and hepatic nodules, involvement of other organs is usually 
assessable and no measurable disease should be present.  
 
5. Bone marrow assessment is irrelevant for determination of a PR if the sample was 
positive before treatment. However, if positive, the c ell type should be specified (eg, 
large-cell lymphoma or small neoplastic B cells). Patients who achieve a CR by the 
above criteria, but who have persistent morphologic bone marrow involvement will be 
considered partial responders.  
 
When the bone marrow w as involved before therapy and a clinical CR was achieved, but with no 
bone marrow assessment after treatment, patients should be considered partial responders.  
 
6. No new sites of disease should be observed.  
 
7. Typically FDG -avid lymphoma: for patients with n o pretreatment PET scan or if the PET 
scan was positive before therapy, the post -treatment PET should be positive in at least 
one previously involved site.  
 
8. Variably FDG -avid lymphomas/FDG -avidity unknown: for patients without a 
pretreatment PET scan, or if a pretreatment PET scan was negative, CT criteria should be 
used.  
 
In patients with follicular lymphoma or mantle -cell lymphoma, a PET scan is only indicated with 
one or at most two residual masses that have regressed by more than 50% on CT; those with  
more than two residual lesions are unlikely to be PET negative and should be considered partial 
responders.  
 
Stable Disease  
Stable disease (SD) is defined as the following:  
 
 
Protocol Version 6.3 67 1. A patient is considered to have SD when he or she fails to attain the criteria 
needed for a CR or PR, but does not fulfill those for progressive disease (see 
Relapsed Disease [after CR]/Progressive Disease [after PR, SD]).  
 
2. Typically FGD -avid lymphomas: the PET should be positive at prior sites of 
disease with no new areas of involv ement on the post -treatment CT or PET.  
 
3. Variably FDG -avid lymphomas/FDG -avidity unknown: for patients without a 
pretreatment PET scan or if the pretreatment PET was negative, there must be no 
change in the size of the previous lesions on the post -treatment CT scan.  
 
Relapsed Disease (after CR)/Progressive Disease (after PR, SD)  
Lymph nodes should be considered abnormal if the long axis is more than 1.5 cm regardless of 
the short axis. If a lymph node has a long axis of 1.1 to 1.5 cm, it should only be con sidered 
abnormal if its short axis is more than 1.0. Lymph nodes ≤ 1.0 × ≤ 1.0 cm will not be considered 
as abnormal for relapse or progressive disease.  
 
1. Appearance of any new lesion more than 1.5 cm in any axis during or at the end of 
therapy, even if ot her lesions are decreasing in size. Increased FDG uptake in a 
previously unaffected site should only be considered relapsed or progressive disease after 
confirmation with other modalities. In patients with no prior history of pulmonary 
lymphoma, new lung n odules identified by CT are mostly benign. Thus, a therapeutic 
decision should not be made solely on the basis of the PET without histologic 
confirmation.  
 
2. At least a 50% increase from nadir in the SPD of any previously involved nodes, or in a 
single invo lved node, or the size of other lesions (eg, splenic or hepatic nodules). To be 
considered progressive disease, a lymph node with a diameter of the short axis of less 
than 1.0 cm must increase by ≥ 50% and to a size of 1.5 × 1.5 cm or more than 1.5 cm in 
the long axis.  
 
3. At least a 50% increase in the longest diameter of any single previously identified node 
more than 1 cm in its short axis.  
 
4. Lesions should be PET positive if observed in a typical FDG -avid lymphoma or the 
lesion was PET positive before ther apy unless the lesion is too small to be detected with 
current PET systems (< 1.5 cm in its long axis by CT).  
 
Measurable extranodal disease should be assessed in a manner similar to that for nodal disease. 
For these recommendations, the spleen is conside red nodal disease. Disease that is only 
assessable (eg, pleural effusions, bone lesions) will be recorded as present or absent only, unless, 
while an abnormality is still noted by imaging studies or physical examination, it is found to be 
histologically ne gative.  
 